<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">TAK</journal-id>
<journal-id journal-id-type="hwp">sptak</journal-id>
<journal-id journal-id-type="nlm-ta">Ther Adv Cardiovasc Dis</journal-id>
<journal-title>Therapeutic Advances in Cardiovascular Disease</journal-title>
<issn pub-type="ppub">1753-9447</issn>
<issn pub-type="epub">1753-9455</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1753944712437359</article-id>
<article-id pub-id-type="publisher-id">10.1177_1753944712437359</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Reviews</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Preventive aspects in peripheral artery disease</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Aggarwal</surname><given-names>Saurabh</given-names></name>
</contrib>
<aff id="aff1-1753944712437359">3333 Green Bay Road, North Chicago, IL-60064, USA</aff>
</contrib-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Loomba</surname><given-names>Rohit Seth</given-names></name>
</contrib>
<aff id="aff2-1753944712437359">Children’s Hospital of Wisconsin/Medical College of Wisconsin Affiliated Hospitals, Wauwatosa, WI, USA</aff>
</contrib-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Arora</surname><given-names>Rohit</given-names></name>
</contrib>
<aff id="aff3-1753944712437359">Department of Medicine, North Chicago VA Medical Center, North Chicago, IL, USA</aff>
</contrib-group>
<author-notes>
<corresp id="corresp1-1753944712437359"><email>drsaurabhaggarwal@gmail.com</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>4</month>
<year>2012</year>
</pub-date>
<volume>6</volume>
<issue>2</issue>
<fpage>53</fpage>
<lpage>70</lpage>
<permissions>
<copyright-statement>© The Author(s), 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>The prevalence of peripheral artery disease is steadily increasing and is associated with significant morbidity, including a significant percentage of amputations. Peripheral artery disease often goes undiagnosed, making its prevention increasingly important. Patients with peripheral arterial disease are at increased risk of adverse cardiovascular outcomes which makes prevention even more important. Several risk factors have been identified in the pathophysiology of peripheral artery disease which should be modified to decrease risk. Smoking, hyperlipidemia, hypertension, and diabetes are among proven risk factors for the development of peripheral artery disease, thus smoking cessation, lipid control, blood pressure control, and glucose control have been tried and shown to be effective in preventing the morbidity associated with this disease. Pharmacologic agents such as aspirin and clopidogrel alone or in combination have been shown to be effective, though risk of bleeding might be increased with the combination. Anticoagulation use is recommended only for acute embolic cases. Other treatment modalities that have been tried or are under investigation are estrogen replacement, naftidrofuryl, pentoxifylline, hyperbaric oxygen, therapeutic angiogenesis, and advanced glycation inhibitors. The treatment for concomitant vascular diseases does not change in the presence of peripheral artery disease, but aggressive management of risk factors should be undertaken in such cases.</p>
</abstract>
<kwd-group>
<kwd>atherosclerosis</kwd>
<kwd>cardiovascular disease</kwd>
<kwd>dyslipidemia</kwd>
<kwd>peripheral arterial disease</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-1753944712437359" sec-type="intro">
<title>Introduction</title>
<p>Peripheral artery disease (PAD), particularly its manifestation in the lower extremity, is often seen in outpatient clinics. PAD is associated with a number of implications for the patient. The patient suffers from pain and disabling symptoms in the limb, and the disease can also lead to many long-term effects on cardiovascular mortality. Prevention of PAD can be a major step in improving quality of life and decreasing overall morbidity and mortality. Recent studies show that both primary and secondary prevention have excellent long-term benefits for the patient. In this article, we review such studies and discuss the means for achieving primary and secondary prevention of PAD.</p>
<p>Most studies estimate that PAD affects approximately 8–10 million people in the USA [<xref ref-type="bibr" rid="bibr180-1753944712437359">Weitz <italic>et al</italic>. 1996</xref>; <xref ref-type="bibr" rid="bibr29-1753944712437359">Criqui, 2001</xref>]. According to a more recent estimate by the SAGE group, the current prevalence of PAD in the USA is about 18 million, with this number estimated to reach 21 million by 2010 [<xref ref-type="bibr" rid="bibr148-1753944712437359">SAGE Group, 2010</xref>]. This increase is mostly attributable to better diagnostic modalities, increased awareness, and the populations studied [<xref ref-type="bibr" rid="bibr166-1753944712437359">Stoffers <italic>et al</italic>. 1996</xref>]. PAD remains largely undiagnosed, leading to grave consequences on patient health and the economy. For example, critical limb ischemia, one of the most severe sequelae of PAD, is estimated to effect nearly 3 million people [<xref ref-type="bibr" rid="bibr148-1753944712437359">SAGE Group, 2010</xref>]. Patients are also at increased risk for developing cardiovascular complications which may result in mortality. Between 40% and 60% of patients with PAD will have some degree of coronary and cerebrovascular disease [<xref ref-type="bibr" rid="bibr31-1753944712437359">Criqui <italic>et al</italic>. 1992</xref>; <xref ref-type="bibr" rid="bibr122-1753944712437359">Newman <italic>et al</italic>. 1993</xref>; <xref ref-type="bibr" rid="bibr179-1753944712437359">Vogt <italic>et al</italic>. 1993</xref>; <xref ref-type="bibr" rid="bibr121-1753944712437359">Ness and Aronow, 1999</xref>]. An Ankle-Brachial Index (ABI) of less than 0.9 is a risk factor for all-cause and cardiovascular mortality [<xref ref-type="bibr" rid="bibr108-1753944712437359">McKenna <italic>et al</italic>. 1991</xref>; <xref ref-type="bibr" rid="bibr107-1753944712437359">McDermott <italic>et al</italic>. 1994</xref>; <xref ref-type="bibr" rid="bibr21-1753944712437359">CAPRIE Steering Committee, 1996</xref>; <xref ref-type="bibr" rid="bibr182-1753944712437359">Wild <italic>et al</italic>. 2006</xref>]. An ABI of less than 0.4 is associated with severe reduction in patient survival [<xref ref-type="bibr" rid="bibr76-1753944712437359">Howell <italic>et al</italic>. 1989</xref>]. In a recent study, it was reported that the participants who had ABI screenings that included arterial waveform analysis had a 78% rate of PAD diagnosis, whereas only 13% of the participants who did not elect ABI screening were diagnosed with PAD based on their symptoms and physical exam [<xref ref-type="bibr" rid="bibr164-1753944712437359">Stephens <italic>et al</italic>. 2011</xref>]. This underscores the importance for primary care physicians to use ABI as a screening tool for PAD.</p>
</sec>
<sec id="section2-1753944712437359">
<title>Atherosclerosis progression and regression</title>
<p>Atherosclerosis plays a major role in PAD and can allow for the prediction of PAD development and severity. Extent of atherosclerosis can also explain the various direct and indirect complications of the disease [<xref ref-type="bibr" rid="bibr125-1753944712437359">Norgren <italic>et al</italic>. 2007</xref>]. Most of the known risk factors for atherosclerosis have also been implicated in the progression of PAD [<xref ref-type="bibr" rid="bibr31-1753944712437359">Criqui <italic>et al</italic>. 1992</xref>; <xref ref-type="bibr" rid="bibr179-1753944712437359">Vogt <italic>et al</italic>. 1993</xref>; <xref ref-type="bibr" rid="bibr109-1753944712437359">Meijer <italic>et al</italic>. 2000</xref>]. Studies have demonstrated that management of atherosclerotic risk factors can lead to prevention of PAD or decrease its severity. Reduction of plaque size, and even complete plaque resolution, is now possible with various interventions.</p>
</sec>
<sec id="section3-1753944712437359">
<title>Definitions</title>
<p>Primary prevention is defined as prevention of initial disease development. Once a disease has developed, diagnosing and treating it at an early asymptomatic stage can prevent further morbidity and this is called secondary prevention. Tertiary prevention is the strategy aimed at preventing, arresting, or delaying the progression of the disease, and also preventing its complications. Gofrit and colleagues defined quaternary prevention as the set of health activities that try to minimize the use of unnecessary interventions in the health system [<xref ref-type="bibr" rid="bibr59-1753944712437359">Gofrit <italic>et al</italic>. 2000</xref>]. This review discusses primary and secondary prevention of PAD.</p>
</sec>
<sec id="section4-1753944712437359">
<title>Risk factors and their management</title>
<p>A multitude of risk factors, both modifiable and nonmodifiable, play a role in the pathophysiology of PAD (<xref ref-type="table" rid="table1-1753944712437359">Table 1</xref>). Nonmodifiable risk factors include being male, age greater than 50 years, being African American, and having a family history of vascular disease [<xref ref-type="bibr" rid="bibr69-1753944712437359">Hirsch <italic>et al</italic>. 2001</xref>; <xref ref-type="bibr" rid="bibr95-1753944712437359">Kullo <italic>et al</italic>. 2003</xref>; <xref ref-type="bibr" rid="bibr153-1753944712437359">Selvin and Erlinger, 2004</xref>].</p>
<table-wrap id="table1-1753944712437359" position="float">
<label>Table 1.</label>
<caption>
<p>Risk factors associated with peripheral arterial disease.</p>
</caption>
<graphic alternate-form-of="table1-1753944712437359" xlink:href="10.1177_1753944712437359-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
</colgroup>
<tbody>
<tr>
<td><bold>Nonmodifiable</bold></td>
</tr>
<tr>
<td>Male gender</td>
</tr>
<tr>
<td>Age &gt; 50</td>
</tr>
<tr>
<td>African American ethnicity</td>
</tr>
<tr>
<td>Family history of vascular disease</td>
</tr>
<tr>
<td><bold>Modifiable</bold></td>
</tr>
<tr>
<td>Smoking</td>
</tr>
<tr>
<td>Hyperlipidemia</td>
</tr>
<tr>
<td>Hypertension</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
</tr>
<tr>
<td>Lifestyle modification – diet, exercise</td>
</tr>
<tr>
<td>Hyperhomocysteinemia</td>
</tr>
<tr>
<td>Inflammation</td>
</tr>
</tbody>
</table>
</table-wrap>
<sec id="section5-1753944712437359">
<title>Smoking</title>
<p>Cigarette smoking is the leading cause in the development and progression of PAD [<xref ref-type="bibr" rid="bibr183-1753944712437359">Willigendael <italic>et al</italic>. 2004</xref>; <xref ref-type="bibr" rid="bibr125-1753944712437359">Norgren <italic>et al</italic>. 2007</xref>]. The diagnosis of PAD can be made about 10 years earlier in smokers compared with nonsmokers [<xref ref-type="bibr" rid="bibr51-1753944712437359">Fowkes <italic>et al</italic>. 1992</xref>; <xref ref-type="bibr" rid="bibr125-1753944712437359">Norgren <italic>et al</italic>. 2007</xref>]. Thus, smoking cessation has been found to lead to a decrease in the incidence of PAD [<xref ref-type="bibr" rid="bibr32-1753944712437359">Dagenais <italic>et al</italic>. 1991</xref>; <xref ref-type="bibr" rid="bibr80-1753944712437359">Ingolfsson <italic>et al</italic>. 1994</xref>]. This association is even more pronounced in patients already suffering from intermittent claudication. Continued smoking has been shown to increase the symptoms of intermittent claudication and leads to an increase in the need for surgical intervention [<xref ref-type="bibr" rid="bibr87-1753944712437359">Jonason and Ringqvist, 1985</xref>; <xref ref-type="bibr" rid="bibr72-1753944712437359">Hirsch <italic>et al</italic>. 1997</xref>]. For those who undergo surgical intervention, vessel patency rates and overall survival are lower in smokers compared with nonsmokers [<xref ref-type="bibr" rid="bibr6-1753944712437359">Ameli <italic>et al</italic>. 1989</xref>]. Whether or not this extends to those who undergo a catheter-based strategy is still under debate [<xref ref-type="bibr" rid="bibr91-1753944712437359">Kastrati <italic>et al</italic>. 1997</xref>; <xref ref-type="bibr" rid="bibr152-1753944712437359">Schillinger <italic>et al</italic>. 2004</xref>]. The benefits of smoking cessation can be seen shortly after cessation, particularly in respect to cardiovascular morbidity and mortality [<xref ref-type="bibr" rid="bibr143-1753944712437359">Rosenberg <italic>et al</italic>. 1990</xref>; <xref ref-type="bibr" rid="bibr32-1753944712437359">Dagenais <italic>et al</italic>. 1991</xref>; <xref ref-type="bibr" rid="bibr80-1753944712437359">Ingolfsson <italic>et al</italic>. 1994</xref>].</p>
<p>Nicotine replacement therapy (NRT) has proven to be fairly effective in smoking cessation. A meta-analysis carried out by Cochrane shows that NRT is successful and safe in all patients and that it should be among the initial methods employed by patients [<xref ref-type="bibr" rid="bibr157-1753944712437359">Silagy <italic>et al</italic>. 1994</xref>]. Bupropion in combination with NRT has been shown to provide additional advantage [<xref ref-type="bibr" rid="bibr79-1753944712437359">Hurt <italic>et al</italic>. 1997</xref>; <xref ref-type="bibr" rid="bibr65-1753944712437359">Hall <italic>et al</italic>. 2002</xref>; <xref ref-type="bibr" rid="bibr172-1753944712437359">Tonstad <italic>et al</italic>. 2003</xref>]. A new therapeutic agent, varenicline, has been shown to be superior to NRT and bupropion [<xref ref-type="bibr" rid="bibr88-1753944712437359">Jorenby <italic>et al</italic>. 2006</xref>; <xref ref-type="bibr" rid="bibr187-1753944712437359">Wu <italic>et al</italic>. 2006</xref>]. Initial concerns of increased incidence of depression associated with varenicline use were dampened by a recent study that failed to find an increased risk of depression in patients treated with varenicline [<xref ref-type="bibr" rid="bibr64-1753944712437359">Gunnell <italic>et al</italic>. 2009</xref>]. Combined treatment with varenicline and NRT has also been shown to be safe and effective [<xref ref-type="bibr" rid="bibr45-1753944712437359">Ebbert <italic>et al</italic>. 2009</xref>]. Recently, safety concerns for varenicline have come up and a meta-analysis has reported increased adverse cardiovascular events for varenicline compared with placebo [<xref ref-type="bibr" rid="bibr159-1753944712437359">Singh <italic>et al</italic>. 2011</xref>].</p>
<p>In spite of the aforementioned, the role of psychological support cannot be disregarded. Thorough psychological counseling helps motivate patients to quit and continue remittance [<xref ref-type="bibr" rid="bibr65-1753944712437359">Hall <italic>et al</italic>. 2002</xref>]. Phone quit-lines [<xref ref-type="bibr" rid="bibr163-1753944712437359">Stead <italic>et al</italic>. 2006</xref>] and Nicotine Anonymous [<xref ref-type="bibr" rid="bibr62-1753944712437359">Green <italic>et al</italic>. 2003</xref>] are also considered to be very effective. Physician advice and the number of counseling sessions can have an influence on the cessation program [<xref ref-type="bibr" rid="bibr65-1753944712437359">Hall <italic>et al</italic>. 2002</xref>]. Smokeless tobacco [<xref ref-type="bibr" rid="bibr16-1753944712437359">Bolinder <italic>et al</italic>. 1994</xref>] and electronic cigarettes [<xref ref-type="bibr" rid="bibr46-1753944712437359">Eissenberg, 2010</xref>] have no benefits and have even been reported to have adverse effects. Self-help books and computerized programs like Quit Meters have some drawbacks and require more research and improvements [<xref ref-type="bibr" rid="bibr118-1753944712437359">Nakajima <italic>et al</italic>. 2008</xref>]. Acupuncture therapy and electrostimulation have also been reported to help in smoking cessation. Though in a systematic review, White and colleagues concluded that there was no consistent evidence that these are effective, though the authors advocated that further research be done due to a lack of bias-free evidence [<xref ref-type="bibr" rid="bibr181-1753944712437359">White <italic>et al</italic>. 2011</xref>].</p>
<p>Smoking cessation is one of the most cost- effective interventions in prevention of adverse cardiovascular events [<xref ref-type="bibr" rid="bibr125-1753944712437359">Norgren <italic>et al</italic>. 2007</xref>].</p>
</sec>
<sec id="section6-1753944712437359">
<title>Hyperlipidemia</title>
<p>There is clear evidence that dyslipidemia can cause and increase the severity of PAD [<xref ref-type="bibr" rid="bibr179-1753944712437359">Vogt <italic>et al</italic>. 1993</xref>; <xref ref-type="bibr" rid="bibr109-1753944712437359">Meijer <italic>et al</italic>. 2000</xref>]. Incidence of new onset intermittent claudication was shown to be significantly lower in patients with coronary disease who were on simvastatin [<xref ref-type="bibr" rid="bibr169-1753944712437359">Terje <italic>et al</italic>. 1998</xref>]. High levels of low-density lipoprotein (LDL), very-low-density lipoprotein (VLDL), triglycerides, and total cholesterol are positive risk factors for PAD [<xref ref-type="bibr" rid="bibr179-1753944712437359">Vogt <italic>et al</italic>. 1993</xref>; <xref ref-type="bibr" rid="bibr109-1753944712437359">Meijer <italic>et al</italic>. 2000</xref>]. High levels of high-density lipoprotein (HDL) and apolipoprotein A-1 are both known to decrease the progression of atheromas [<xref ref-type="bibr" rid="bibr125-1753944712437359">Norgren <italic>et al</italic>. 2007</xref>]. The ratio of total cholesterol to HDL fraction has been shown to be the best predictor of PAD development [<xref ref-type="bibr" rid="bibr140-1753944712437359">Ridker <italic>et al</italic>. 2001</xref>]. Apolipoprotein (Apo)-E [<xref ref-type="bibr" rid="bibr145-1753944712437359">Rouis <italic>et al</italic>. 1999</xref>] has also been shown in several animal studies to decrease the risk of atherosclerosis and requires further research to detect its risks and benefits in humans. Recently, Gary and colleagues have shown that an increased level of Apo-B, a constituent of all atherogenic lipoproteins, is associated with increased rate of stent restenosis [<xref ref-type="bibr" rid="bibr54-1753944712437359">Gary <italic>et al</italic>. 2010</xref>]. Target LDL levels are less than 2.59 mmol/liter (100 mg/dl) in asymptomatic patients with PAD without other clinical evidence of cardiovascular disease and less than 1.81 mmol/liter (70 mg/dl) in patients with concomitant disease in other arterial beds [<xref ref-type="bibr" rid="bibr125-1753944712437359">Norgren <italic>et al</italic>. 2007</xref>].</p>
<p>Lifestyle modifications should be attempted before pharmacologic intervention [<xref ref-type="bibr" rid="bibr125-1753944712437359">Norgren <italic>et al</italic>. 2007</xref>]. Patients should be advised to adopt a low-fat diet and maintain a regular exercise regimen. Once these have proven to be unsustainable for patients, pharmacologic treatment may be initiated. Statins have been shown to have anti-inflammatory effects and decrease plaque size, and should be the primary drugs of choice [<xref ref-type="bibr" rid="bibr67-1753944712437359">Heart Protection Study Collaborative Group, 2002</xref>; <xref ref-type="bibr" rid="bibr123-1753944712437359">Nissen <italic>et al</italic>. 2006</xref>]. Simvastatin and pravastatin are both statins that have been thoroughly studied in this setting. In patients with PAD, statins have been shown to increase pain-free walking time, a finding that may be independent of the cholesterol-lowering action of statins [<xref ref-type="bibr" rid="bibr114-1753944712437359">Mohler <italic>et al</italic>. 2003</xref>]. Fibrates can be given to people who are intolerant to statins as they help lower triglyceride levels and increase HDL levels. Some studies show that they even improve insulin resistance [<xref ref-type="bibr" rid="bibr149-1753944712437359">Samuel <italic>et al</italic>. 2009</xref>; <xref ref-type="bibr" rid="bibr89-1753944712437359">Jun <italic>et al</italic>. 2010</xref>]. Niacin has also been shown to decrease LDL, VLDL, triglycerides, and total cholesterol, while simultaneously increasing HDL [<xref ref-type="bibr" rid="bibr48-1753944712437359">Elam <italic>et al</italic>. 2000</xref>]. It may also lead to lower levels of Apo-A [<xref ref-type="bibr" rid="bibr84-1753944712437359">Jin <italic>et al</italic>. 1997</xref>]. Niacin has recently been found to be superior to ezetemibe when used in combination with statins [<xref ref-type="bibr" rid="bibr177-1753944712437359">Villines <italic>et al</italic>. 2010</xref>]. The adverse effects of niacin, particularly skin flushing, are usually preventable by pretreatment with aspirin [<xref ref-type="bibr" rid="bibr22-1753944712437359">Cefali <italic>et al</italic>. 2007</xref>]. Laropripant, used in Europe to decrease niacin-induced flushing, failed to received US Food and Drug Administration approval in this role but additional data about its efficacy may impact this decision [<xref ref-type="bibr" rid="bibr78-1753944712437359">Hughes, 2008</xref>; <xref ref-type="bibr" rid="bibr131-1753944712437359">Paolini <italic>et al</italic>. 2008</xref>].</p>
<p>Bile acid sequestrants are not frequently used in the current era of statins. However, they may still be beneficial in some patients due to their lack of systemic toxicity [<xref ref-type="bibr" rid="bibr81-1753944712437359">Insull, 2006</xref>] and can be combined with statins instead of fibrates if there is a risk of rhabdomyolysis with the latter. Ezetemibe, which works by decreasing cholesterol absorption in the gut, has not been shown to improve clinical outcomes. In some studies, it has been even been shown to worsen the outcome and hence is recommended only as a last resort [<xref ref-type="bibr" rid="bibr86-1753944712437359">John <italic>et al</italic>. 2005</xref>; <xref ref-type="bibr" rid="bibr112-1753944712437359">Mitka, 2008</xref>]. Cholesterol enzyme transfer protein inhibitors [<xref ref-type="bibr" rid="bibr34-1753944712437359">Davidson <italic>et al</italic>. 2006</xref>] and squalene synthase inhibitors [<xref ref-type="bibr" rid="bibr33-1753944712437359">Davidson, 2007</xref>] are currently being investigated for their role in lowering lipid levels and other potential benefits.</p>
</sec>
<sec id="section7-1753944712437359">
<title>Hypertension</title>
<p>Hypertension is an independent risk factor for PAD and can increase PAD risk threefold [<xref ref-type="bibr" rid="bibr117-1753944712437359">Murabito <italic>et al</italic>. 1997</xref>]. Isolated systolic hypertension is associated with increased arterial stiffness and progression of atherosclerosis. Even a small reduction in blood pressure can lead to a 16%, 30%, and 40% decrease in the incidence of coronary heart disease, stroke, and overall mortality, respectively [<xref ref-type="bibr" rid="bibr119-1753944712437359">Neal <italic>et al</italic>. 2000</xref>]. Some studies have shown that the use of certain antihypertensives can even be beneficial in patients who are normotensive with prior history of vascular events, such as stroke, for prevention of adverse vascular events [<xref ref-type="bibr" rid="bibr135-1753944712437359">PROGRESS Collaborative Group, 2001</xref>]. The target blood pressure is less than 140/90 mmHg except for patients with diabetes or renal insufficiency in whom target blood pressure should be less than 130/80 mmHg [<xref ref-type="bibr" rid="bibr125-1753944712437359">Norgren <italic>et al</italic>. 2007</xref>].</p>
<p>According to Joint National Committee VII (JNC VII) and European guidelines [<xref ref-type="bibr" rid="bibr24-1753944712437359">Chobanian <italic>et al</italic>. 2003</xref>; <xref ref-type="bibr" rid="bibr50-1753944712437359">European Society of Hypertension–European Society of Cardiology, 2003</xref>] thiazides and angiotensin-converting enzyme (ACE) inhibitors should be considered as first-line drugs. These drugs have various beneficial effects in patients with PAD. Thiazides are especially beneficial in the treatment of isolated systolic hypertension seen in older people [<xref ref-type="bibr" rid="bibr129-1753944712437359">Ott <italic>et al</italic>. 2003</xref>]. However, low doses are beneficial only in mild to moderate hypertension and when renal function is normal. They can cause glucose intolerance or worsening of glycemic control and hence ACE inhibitors should be used in patients with diabetics. ACE inhibitors have been shown to decrease the risk of diabetic nephropathy and mortality associated with congestive heart failure [<xref ref-type="bibr" rid="bibr188-1753944712437359">Yusuf <italic>et al</italic>. 2000</xref>; <xref ref-type="bibr" rid="bibr135-1753944712437359">PROGRESS Collaborative Group, 2001</xref>; <xref ref-type="bibr" rid="bibr100-1753944712437359">Lewis <italic>et al</italic>. 2001</xref>]. ACE inhibitors may even decrease the incidence of arrhythmias and sudden death by increasing parasympathetic activity [<xref ref-type="bibr" rid="bibr3-1753944712437359">Ajayi <italic>et al</italic>. 1985</xref>]. PAD patients gain even more benefit than those without PAD as shown by subgroup analysis [<xref ref-type="bibr" rid="bibr188-1753944712437359">Yusuf <italic>et al</italic>. 2000</xref>; <xref ref-type="bibr" rid="bibr128-1753944712437359">Ostergren <italic>et al</italic>. 2004</xref>]. Patients on ACE inhibitors have also been shown to have a decreased need for revascularization procedures [<xref ref-type="bibr" rid="bibr188-1753944712437359">Yusuf <italic>et al</italic>. 2000</xref>]. Monotherapy should always be tried initially, with dual or triple therapy tried only if monotherapy fails to adequately achieve the desired results. Cost effectiveness of ACE inhibitors also makes them of particular use [<xref ref-type="bibr" rid="bibr97-1753944712437359">Lamy <italic>et al</italic>. 2003</xref>].</p>
<p>Once considered contraindicated for use in patients with PAD due to fear of worsening of claudication symptoms, β blockers are now considered safe for use [<xref ref-type="bibr" rid="bibr136-1753944712437359">Radack and Deck, 1991</xref>]. Patients with coronary disease may gain additional benefits in the form of decreased cardiovascular morbidity and mortality with β blockade [<xref ref-type="bibr" rid="bibr125-1753944712437359">Norgren <italic>et al</italic>. 2007</xref>]. β Blockers should be given perioperatively to patients with PAD undergoing vascular surgeries to decrease risk of adverse cardiovascular events during, and after, surgery if there are no contraindications [<xref ref-type="bibr" rid="bibr134-1753944712437359">Poldermans <italic>et al</italic>. 1999</xref>, <xref ref-type="bibr" rid="bibr133-1753944712437359">2001]</xref>.</p>
<p>Thus, all at-risk or diagnosed patients with PAD and hypertension should be initially started on thiazides or ACE inhibitors. Other therapies may be considered in special circumstances [<xref ref-type="bibr" rid="bibr24-1753944712437359">Chobanian <italic>et al</italic>. 2003</xref>]. Newer modalities for hypertension like coenzyme Q [<xref ref-type="bibr" rid="bibr144-1753944712437359">Rosenfeldt <italic>et al</italic>. 2007</xref>] and blood pressure vaccine [<xref ref-type="bibr" rid="bibr4-1753944712437359">Alain <italic>et al</italic>. 2008</xref>] are still under research and have shown some promise in lowering blood pressure.</p>
</sec>
<sec id="section8-1753944712437359">
<title>Diabetes mellitus</title>
<p>Patients with diabetes mellitus have a nearly fourfold greater risk of developing PAD than those without diabetes mellitus [<xref ref-type="bibr" rid="bibr90-1753944712437359">Kannel <italic>et al</italic>. 1970</xref>]. Claudication has been shown to have doubled the prevalence in diabetics. There is approximately a 26% increased risk of PAD and a 28% increased risk of death for every 1% increase in HbA<sub>1</sub>C level in diabetics. This finding is independent of age, blood pressure, cholesterol, and smoking status [<xref ref-type="bibr" rid="bibr153-1753944712437359">Selvin and Erlinger, 2004</xref>]. PAD in patients with diabetes is also less amenable to revascularization, being associated with lower patency rates post revascularization [<xref ref-type="bibr" rid="bibr20-1753944712437359">Bypass Angioplasty Revascularization Investigation Investigators, 1996</xref>]. Due to increased risk of infections and neuropathy, patients with diabetes are more prone to complications in PAD and experience higher amputation rates than those without diabetes [<xref ref-type="bibr" rid="bibr39-1753944712437359">Donnelly <italic>et al</italic>. 2000</xref>; <xref ref-type="bibr" rid="bibr23-1753944712437359">Centers for Disease Control and Prevention, 2001</xref>; <xref ref-type="bibr" rid="bibr85-1753944712437359">Johannesson <italic>et al</italic>. 2009</xref>]. Even insulin resistance in the absence of diabetes increases the risk of PAD by 40–50% [<xref ref-type="bibr" rid="bibr116-1753944712437359">Muntner <italic>et al</italic>. 2005</xref>].</p>
<p>For this reason, the American Diabetes Association recommends monitoring ABI once every 5 years in patients with diabetes. Additionally, all those with diabetes and ulcers should be checked for PAD [<xref ref-type="bibr" rid="bibr7-1753944712437359">American Diabetes Association, 2010</xref>]. Though some studies have failed to show a risk reduction for PAD with strict glycemic control [<xref ref-type="bibr" rid="bibr38-1753944712437359">Diabetes Control and Complications Trial, 1995</xref>; <xref ref-type="bibr" rid="bibr174-1753944712437359">UK Prospective Diabetes Study (UKPDS) Group, 1998</xref>] its effects are clear in secondary prevention confirmed by lower rates of coronary and cerebrovascular events [<xref ref-type="bibr" rid="bibr40-1753944712437359">Dormandy <italic>et al</italic>. 2005</xref>]. Additional studies are still needed to investigate this association.</p>
<p>The goals for treatment are HbA<sub>1</sub>C levels less than 7%, or even less than 6%, but only if it can be achieved while ensuring that there are no hypoglycemic episodes [<xref ref-type="bibr" rid="bibr125-1753944712437359">Norgren <italic>et al</italic>. 2007</xref>]. All patients with diabetes should be supervised by a registered dietician for a medical nutrition therapy [<xref ref-type="bibr" rid="bibr7-1753944712437359">American Diabetes Association, 2010</xref>]. Lifestyle modifications take precedence over all other therapies. If they fail to control glucose levels, drug therapy should be started. The therapy should be tailored to an individual’s needs and other comorbidities. All patients with diabetes should have annual lower extremity examinations to monitor for ulcers, which are early signs of PAD. All patients should be counseled thoroughly about adequate foot care [<xref ref-type="bibr" rid="bibr7-1753944712437359">American Diabetes Association, 2010</xref>]. Strict blood pressure control must also be stressed to patients with diabetes [<xref ref-type="bibr" rid="bibr66-1753944712437359">Hansson <italic>et al</italic>. 1998</xref>].</p>
</sec>
<sec id="section9-1753944712437359">
<title>Lifestyle modification</title>
<p>Lifestyle modifications remain the most cost-effective interventions for the prevention of complications and sequelae in patients with PAD. These include cessation of smoking [<xref ref-type="bibr" rid="bibr75-1753944712437359">Hobbs and Bradbury, 2003</xref>], diet changes [<xref ref-type="bibr" rid="bibr110-1753944712437359">Merchant <italic>et al</italic>. 2003</xref>; <xref ref-type="bibr" rid="bibr92-1753944712437359">Khan <italic>et al</italic>. 2005</xref>] and exercise [<xref ref-type="bibr" rid="bibr103-1753944712437359">Lowensteyn <italic>et al</italic>. 2000</xref>]. Even modest weight reduction has been shown to be beneficial in improving insulin resistance, dyslipidemia, and hypertension control [<xref ref-type="bibr" rid="bibr93-1753944712437359">Klein <italic>et al</italic>. 2004</xref>], factors frequently seen in patients with PAD.</p>
<sec id="section10-1753944712437359">
<title>Diet</title>
<p>Diet changes should be made according to nutritional requirements and comorbidities. Consultation with a dietician can often be helpful for patients, particularly those with significant comorbidities. According to American Diabetes Association guidelines [<xref ref-type="bibr" rid="bibr7-1753944712437359">American Diabetes Association, 2010</xref>], patients should commit to a diet low in carbohydrate and fat content. Saturated fat intake should be limited to less than 7% of total calorie intake with a reduction in trans fat. A daily dietary fiber intake of 14 g/1000 kcal and foods containing whole grains should also be encouraged [<xref ref-type="bibr" rid="bibr110-1753944712437359">Merchant <italic>et al</italic>. 2003</xref>; <xref ref-type="bibr" rid="bibr7-1753944712437359">American Diabetes Association, 2010</xref>]. Eating small portions of food more frequently during the day, rather than a few large meals, has also shown benefits. Alcohol intake should be limited to one and two drinks per day for women and men, respectively. Supplementation with vitamin C, vitamin E, and chromium has failed to show significant benefits and is not recommended. Patients with hypertension should reduce salt intake [<xref ref-type="bibr" rid="bibr9-1753944712437359">Appel <italic>et al</italic>. 2001</xref>; <xref ref-type="bibr" rid="bibr147-1753944712437359">Sacks <italic>et al</italic>. 2001</xref>].</p>
</sec>
<sec id="section11-1753944712437359">
<title>Exercise</title>
<p>People without symptoms of claudication should exercise for at least 150 min per week with heart rate being maintained at 50–70% of age-appropriate maximums. In the absence of contraindications, resistance training should be done at least three times a week [<xref ref-type="bibr" rid="bibr7-1753944712437359">American Diabetes Association, 2010</xref>]. Patients with PAD should exercise three times a week to a level that brings on moderate claudication followed by rest [<xref ref-type="bibr" rid="bibr71-1753944712437359">Hirsch <italic>et al</italic>. 2006</xref>]. Exercise regimens like treadmill walking are sufficient. Supervised exercise regimens have been proven to give better results and should be recommended to patients [<xref ref-type="bibr" rid="bibr53-1753944712437359">Gardner and Poehlman, 1995</xref>; <xref ref-type="bibr" rid="bibr71-1753944712437359">Hirsch <italic>et al</italic>. 2006</xref>; <xref ref-type="bibr" rid="bibr125-1753944712437359">Norgren <italic>et al</italic>. 2007</xref>]. An exercise period of at least 3 months is usually required to demonstrate the benefits [<xref ref-type="bibr" rid="bibr71-1753944712437359">Hirsch <italic>et al</italic>. 2006</xref>].</p>
</sec></sec>
<sec id="section12-1753944712437359">
<title>Hyperhomocysteinemia</title>
<p>The association of hyperhomocysteinemia with atherosclerosis is widely recognized [<xref ref-type="bibr" rid="bibr18-1753944712437359">Boushey <italic>et al</italic>. 1995</xref>]. It might even be a stronger risk factor for PAD than for coronary artery disease (CAD), but the association has not been noted in all studies [<xref ref-type="bibr" rid="bibr168-1753944712437359">Taylor <italic>et al</italic>. 1991</xref>; <xref ref-type="bibr" rid="bibr140-1753944712437359">Ridker <italic>et al</italic>. 2001</xref>]. High levels of homocysteine have been seen in up to 30% of patients with PAD [<xref ref-type="bibr" rid="bibr125-1753944712437359">Norgren <italic>et al</italic>. 2007</xref>] but studies have failed to show that lowering homocysteine levels decreases cardiovascular mortality. In fact, some studies have even reported adverse effects with vitamin or folate therapy aimed at decreasing homocysteine levels [<xref ref-type="bibr" rid="bibr17-1753944712437359">Bonaa <italic>et al</italic>. 2006</xref>; <xref ref-type="bibr" rid="bibr102-1753944712437359">Lonn <italic>et al</italic>. 2006</xref>; <xref ref-type="bibr" rid="bibr178-1753944712437359">VITATOPS Trial Study Group, 2010</xref>]. This occurrence may be due to increased plaque growth because of direct effects or gene methylation in the vascular cells [<xref ref-type="bibr" rid="bibr141-1753944712437359">Rippel <italic>et al</italic>. 2007</xref>]. More research is needed to establish the role of lowering homocysteine levels, and until then, pharmacologic treatment with the aim of decreasing homocysteine levels to decrease cardiovascular morbidity and mortality should be avoided [<xref ref-type="bibr" rid="bibr125-1753944712437359">Norgren <italic>et al</italic>. 2007</xref>].</p>
</sec>
<sec id="section13-1753944712437359">
<title>Inflammation</title>
<p>Various studies have found that increased levels of inflammatory markers are associated with increased atherosclerosis and cardiovascular events. C-reactive protein (CRP), fibrinogen, complement component C5a, monocyte counts, and plasma tissue factors have all been demonstrated to be predictors of restenosis after revascularization [<xref ref-type="bibr" rid="bibr140-1753944712437359">Ridker <italic>et al</italic>. 2001</xref>; <xref ref-type="bibr" rid="bibr137-1753944712437359">Ray <italic>et al</italic>. 2007</xref>; <xref ref-type="bibr" rid="bibr161-1753944712437359">Speidl <italic>et al</italic>. 2007</xref>]. Data from various studies, however, have been conflicting. Of all these inflammatory markers, CRP levels have been most consistently found to be an independent risk factor for PAD and restenosis [<xref ref-type="bibr" rid="bibr139-1753944712437359">Ridker <italic>et al</italic>. 1998</xref>; <xref ref-type="bibr" rid="bibr151-1753944712437359">Schillinger <italic>et al</italic>. 2003</xref>]. High-sensitivity CRP has also been shown to predict cardiovascular mortality in patients with PAD [<xref ref-type="bibr" rid="bibr30-1753944712437359">Criqui <italic>et al</italic>. 2010</xref>; <xref ref-type="bibr" rid="bibr175-1753944712437359">Urbonaviciene <italic>et al</italic>. 2011</xref>]. Statins have also been shown to reduce high-sensitivity CRP levels in patients with PAD [<xref ref-type="bibr" rid="bibr2-1753944712437359">Aguilar <italic>et al</italic>. 2009</xref>]. Additionally, platelets form microthrombi and secrete cytokines responsible for increasing atheroma size and remodeling. Increased cytokines, adhesion molecules, and chemokines causing increased vascular smooth muscle proliferation are all central to the development of restenosis [<xref ref-type="bibr" rid="bibr26-1753944712437359">Clowes <italic>et al</italic>. 1983</xref>; <xref ref-type="bibr" rid="bibr142-1753944712437359">Rollins, 1997</xref>; <xref ref-type="bibr" rid="bibr101-1753944712437359">Libby and Simon, 2001</xref>].</p>
</sec>
<sec id="section14-1753944712437359">
<title>Antiplatelet therapy</title>
<sec id="section15-1753944712437359">
<title>Aspirin</title>
<p>Aspirin or acetyl salicylic acid has been shown to cause a significant decrease in the progression of PAD. It has been studied extensively for its role in reduction of cardiovascular events and associated mortality and almost all the studies have proven its benefit. In patients with PAD and CAD or cerebrovascular disease, aspirin should be used in doses ranging from 75 to 325 mg [<xref ref-type="bibr" rid="bibr25-1753944712437359">Clagett <italic>et al</italic>. 2004</xref>; <xref ref-type="bibr" rid="bibr125-1753944712437359">Norgren <italic>et al</italic>. 2007</xref>]. Even in the absence of CAD or cerebrovascular disease, it offers protective effects. The benefit of even 150 mg of aspirin has been shown to be comparable to high-dose therapy and features lower incidence of gastrointestinal side effects like bleeding [<xref ref-type="bibr" rid="bibr43-1753944712437359">Dutch TIA Trial Study Group, 1991</xref>]. Studies have shown the decreased need for revascularization procedures in patients with PAD who were on aspirin [<xref ref-type="bibr" rid="bibr57-1753944712437359">Giansante <italic>et al</italic>. 1990</xref>; <xref ref-type="bibr" rid="bibr60-1753944712437359">Goldhaber <italic>et al</italic>. 1992</xref>]. After revascularization, aspirin use leads to decreased incidence of restenosis [<xref ref-type="bibr" rid="bibr25-1753944712437359">Clagett <italic>et al</italic>. 2004</xref>]. Favorable effects on coagulation profile, ABI [<xref ref-type="bibr" rid="bibr57-1753944712437359">Giansante <italic>et al</italic>. 1990</xref>] and angiographical progression [<xref ref-type="bibr" rid="bibr73-1753944712437359">Hirsh <italic>et al</italic>. 1995</xref>] of the disease have been shown in patients taking aspirin. Aspirin has also been shown to inhibit the formation of advanced glycation end products (AGEs).</p>
</sec>
<sec id="section16-1753944712437359">
<title>Thienopyridines</title>
<p>Thienopyridines include drugs such as clopidogrel, ticlopidine, and prasugrel. These have been of particular benefit in patients intolerant of aspirin. Though the overall advantages of clopidogrel over aspirin are modest [<xref ref-type="bibr" rid="bibr21-1753944712437359">CAPRIE Steering Committee, 1996</xref>], clopidogrel has been shown to be effective in reducing risk of myocardial infarction, stroke, and death related to vascular diseases in patients with PAD [<xref ref-type="bibr" rid="bibr25-1753944712437359">Clagett <italic>et al</italic>. 2004</xref>; <xref ref-type="bibr" rid="bibr125-1753944712437359">Norgren <italic>et al</italic>. 2007</xref>]. Some studies report that clopidogrel may be superior to aspirin in controlling ischemic events [<xref ref-type="bibr" rid="bibr21-1753944712437359">CAPRIE Steering Committee, 1996</xref>; <xref ref-type="bibr" rid="bibr15-1753944712437359">Bhatt <italic>et al</italic>. 2000</xref>; <xref ref-type="bibr" rid="bibr12-1753944712437359">Basili <italic>et al</italic>. 2010</xref>]. Higher cost and the risk of thrombocytopenia and leukopenia still leave aspirin as the preferred drug in patients with no contraindications [<xref ref-type="bibr" rid="bibr61-1753944712437359">Gorelick <italic>et al</italic>. 1999</xref>; <xref ref-type="bibr" rid="bibr25-1753944712437359">Clagett <italic>et al</italic>. 2004</xref>]. However, clopidogrel might be more cost effective in patients at very high risk of recurrent ischemic events [<xref ref-type="bibr" rid="bibr74-1753944712437359">Ho <italic>et al</italic>. 2004</xref>]. Ticlopidine is not used frequently now [<xref ref-type="bibr" rid="bibr25-1753944712437359">Clagett <italic>et al</italic>. 2004</xref>] due to associated risk of severe thrombocytopenia and neutropenia [<xref ref-type="bibr" rid="bibr99-1753944712437359">Leon <italic>et al</italic>. 1998</xref>; <xref ref-type="bibr" rid="bibr13-1753944712437359">Bhatt <italic>et al</italic>. 2002</xref>]. Prasugrel was approved by the FDA in 2009 for reduction of thrombotic events in patients with acute coronary events undergoing percutaneous coronary intervention. Though shown to be superior to clopidogrel when combined with aspirin in preventing adverse cardiovascular events, the increased risk of bleeding compared with clopidogrel is of concern [<xref ref-type="bibr" rid="bibr185-1753944712437359">Wiviott <italic>et al</italic>. 2007a</xref>]. Its sustained and more efficacious platelet inhibition, compared with clopidogrel, may make it the agent of choice in the near future [<xref ref-type="bibr" rid="bibr186-1753944712437359">Wiviott <italic>et al</italic>. 2007b</xref>]. However, its role in management of PAD needs to be studied more extensively.</p>
</sec>
<sec id="section17-1753944712437359">
<title>Cilostazol</title>
<p>Cilostazol can be used as an adjunctive therapy in patients with PAD. However, it should never replace treatment with aspirin or clopidogrel [<xref ref-type="bibr" rid="bibr25-1753944712437359">Clagett <italic>et al</italic>. 2004</xref>]. Cilostazol has not shown any benefit in reduction of cardiovascular morbidity or all-cause mortality [<xref ref-type="bibr" rid="bibr28-1753944712437359">Craig, 2001</xref>]. Improvements in claudication symptoms and walking distance in patients with PAD are evident [<xref ref-type="bibr" rid="bibr36-1753944712437359">Dawson <italic>et al</italic>. 1998</xref>; <xref ref-type="bibr" rid="bibr138-1753944712437359">Regensteiner <italic>et al</italic>. 2002</xref>; <xref ref-type="bibr" rid="bibr170-1753944712437359">Thompson <italic>et al</italic>. 2002</xref>] lead to improved quality of life [<xref ref-type="bibr" rid="bibr36-1753944712437359">Dawson <italic>et al</italic>. 1998</xref>; <xref ref-type="bibr" rid="bibr138-1753944712437359">Regensteiner <italic>et al</italic>. 2002</xref>]. It has also been shown to have favorable effects on lipoprotein profile, particularly increasing HDL and reducing triglycerides [<xref ref-type="bibr" rid="bibr47-1753944712437359">Elam <italic>et al</italic>. 1998</xref>]. Cilostazol can be safely given with other antiplatelets like aspirin and clopidogrel without any increased risk of bleeding [<xref ref-type="bibr" rid="bibr41-1753944712437359">Douglas <italic>et al</italic>. 2003</xref>]. When given after an endoluminal revascularization process, it has been consistently shown to decrease the risk of restenosis [<xref ref-type="bibr" rid="bibr82-1753944712437359">Ishii <italic>et al</italic>. 2008</xref>; <xref ref-type="bibr" rid="bibr126-1753944712437359">Osamu <italic>et al</italic>. 2008</xref>; <xref ref-type="bibr" rid="bibr160-1753944712437359">Soga <italic>et al</italic>. 2009</xref>]. Though its use in heart failure was discouraged because of its similarity to milrinone, which is contraindicated in heart failure [<xref ref-type="bibr" rid="bibr130-1753944712437359">Packer <italic>et al</italic>. 1991</xref>], recent studies show that it might actually improve cardiac function by decreasing secondary remodeling [<xref ref-type="bibr" rid="bibr150-1753944712437359">Sanganalmath <italic>et al</italic>. 2008</xref>]. It should be noted that though the drug has been approved by the FDA, it has not been approved for use in many countries in Europe.</p>
</sec>
<sec id="section18-1753944712437359">
<title>Dipyridamole</title>
<p>Dipyridamole has been primarily used in prevention of stroke and transient ischemic attacks [<xref ref-type="bibr" rid="bibr49-1753944712437359">ESPRIT Study Group, 2006</xref>]. Its role in PAD still needs investigation. Its use is limited mostly to combination therapy with aspirin [<xref ref-type="bibr" rid="bibr68-1753944712437359">Hess <italic>et al</italic>. 1985</xref>; <xref ref-type="bibr" rid="bibr27-1753944712437359">Clyne <italic>et al</italic>. 1987</xref>].</p>
</sec>
<sec id="section19-1753944712437359">
<title>Picotamide</title>
<p>Picotamide is still in its early days of evaluation. It has been shown to be particularly effective in patients with PAD and diabetes [<xref ref-type="bibr" rid="bibr11-1753944712437359">Balsano and Violi, 1993</xref>; <xref ref-type="bibr" rid="bibr120-1753944712437359">Neri Serneri <italic>et al</italic>. 2004</xref>]. In a recent meta-analysis, there were trends for favorable outcome after picotamide therapy but statistical significance could not be demonstrated [<xref ref-type="bibr" rid="bibr12-1753944712437359">Basili <italic>et al</italic>. 2010</xref>]. More data are required at present.</p>
</sec>
<sec id="section20-1753944712437359">
<title>Combination therapy</title>
<p>Although the use of aspirin in combination with clopidogrel has been shown to be superior to aspirin alone in patients with acute coronary syndromes [<xref ref-type="bibr" rid="bibr189-1753944712437359">Yusuf <italic>et al</italic>. 2001</xref>], the recent Clopidogrel and Acetylsalicylic Acid in Bypass Surgery for Peripheral Arterial Disease (CASPAR) trial found no evidence of increased benefit in patients with PAD [<xref ref-type="bibr" rid="bibr83-1753944712437359">Jill <italic>et al</italic>. 2010</xref>]. Hence, its use is not recommended [<xref ref-type="bibr" rid="bibr125-1753944712437359">Norgren <italic>et al</italic>. 2007</xref>]. The CHARISMA trial concluded that the benefits of the combination were marginal while the risk of bleeding was significant [<xref ref-type="bibr" rid="bibr14-1753944712437359">Bhatt <italic>et al</italic>. 2006</xref>].</p>
<p>Combination therapy with aspirin and dipyridamole has been shown to more effective than aspirin alone in delaying the progression of PAD and increasing the patency of grafts. This combination has been shown to have some benefit in patients with PAD in small trials [<xref ref-type="bibr" rid="bibr68-1753944712437359">Hess <italic>et al</italic>. 1985</xref>; <xref ref-type="bibr" rid="bibr27-1753944712437359">Clyne <italic>et al</italic>. 1987</xref>]. Larger trials are needed to further validate these results.</p>
<p>Triple therapy with aspirin, clopidogrel, and dipyridamole was studied for prevention of stroke, leading to high incidence of bleeding events [<xref ref-type="bibr" rid="bibr162-1753944712437359">Sprigg <italic>et al</italic>. 2008</xref>]. Recently, a meta-analysis reported that triple therapy based on glycoprotein IIb/IIIa was more effective than aspirin-based dual therapy in reducing vascular events in patients with acute coronary syndromes, but had no beneficial effect and was associated with increase in transfusions and thrombocytopenia in patients undergoing elective percutaneous coronary intervention [<xref ref-type="bibr" rid="bibr55-1753944712437359">Geeganage <italic>et al</italic>. 2010</xref>]. These combinations have not been studied in patients with PAD and should not be tried until more supportive data are available. Triple therapy with aspirin, clopidogrel, and cilostazol has been shown to be safe and effective in patients with PAD as discussed above [<xref ref-type="bibr" rid="bibr41-1753944712437359">Douglas <italic>et al</italic>. 2003</xref>].</p>
</sec></sec>
<sec id="section21-1753944712437359">
<title>Anticoagulation</title>
<p>There are currently no recommendations to utilize anticoagulants for prevention of cardiovascular events in patients with PAD [<xref ref-type="bibr" rid="bibr71-1753944712437359">Hirsch <italic>et al</italic>. 2006</xref>] or in those undergoing bypass [<xref ref-type="bibr" rid="bibr25-1753944712437359">Clagett <italic>et al</italic>. 2004</xref>]. Compared with aspirin alone, their combination with aspirin is not more effective in preventing cardiovascular morbidity and mortality [<xref ref-type="bibr" rid="bibr8-1753944712437359">Anand <italic>et al</italic>. 2007</xref>]. This combination may have some benefit in preventing graft occlusion in high-risk cases [<xref ref-type="bibr" rid="bibr25-1753944712437359">Clagett <italic>et al</italic>. 2004</xref>; <xref ref-type="bibr" rid="bibr125-1753944712437359">Norgren <italic>et al</italic>. 2007</xref>]. Anticoagulants might also have a better effect on patency after bypass surgeries [<xref ref-type="bibr" rid="bibr42-1753944712437359">Dutch Bypass Oral Anticoagulants or Aspirin Study, 2000</xref>]. The use of anticoagulants should be limited to treatment of all patients with acute limb ischemia (ALI) and long-term prophylaxis when ALI occurs due to embolism [<xref ref-type="bibr" rid="bibr125-1753944712437359">Norgren <italic>et al</italic>. 2007</xref>]. Anticoagulation should be started immediately for patients with ALI, but it must be kept in mind that they can increase the risk of bleeding if amputation has to be performed. Heparin should be followed by warfarin for 3–6 months or longer and there are no clear-cut guidelines on the duration of therapy [<xref ref-type="bibr" rid="bibr125-1753944712437359">Norgren <italic>et al</italic>. 2007</xref>]. Atrial fibrillation has recently been shown to be independently associated with worse outcomes in patients with PAD [<xref ref-type="bibr" rid="bibr184-1753944712437359">Winkel <italic>et al</italic>. 2010</xref>]. In patients with atrial fibrillation, anticoagulation with warfarin is clearly better than aspirin in preventing embolic lower limb ischemia and stroke [<xref ref-type="bibr" rid="bibr167-1753944712437359">Stroke Prevention in Atrial Fibrillation II Study, 1994</xref>]. But the benefits should be compared with the risks of bleeding, especially in older people. This is especially important in the light of recent evidence which suggests that bleeding is independently associated with subsequent ischemic events [<xref ref-type="bibr" rid="bibr176-1753944712437359">Van Hattum <italic>et al</italic>. 2009</xref>].</p>
</sec>
<sec id="section22-1753944712437359">
<title>Some other drugs and modalities</title>
<sec id="section23-1753944712437359">
<title>Estrogen replacement therapy</title>
<p>Although estrogen was previously thought to have cardioprotective benefits, studies have demonstrated that estrogen therapy is not recommended for management of PAD. It does not decrease the risk of PAD in patients with CAD [<xref ref-type="bibr" rid="bibr77-1753944712437359">Hsia <italic>et al</italic>. 2000</xref>]. Also it has been noted that women on hormone replacement therapy may experience increased failure rates after revascularization or bypass procedures [<xref ref-type="bibr" rid="bibr171-1753944712437359">Timaran <italic>et al</italic>. 2000</xref>]. This effect of PAD might be due to its effect on smooth muscle cell motility and matrix metalloproteinases [<xref ref-type="bibr" rid="bibr127-1753944712437359">Oscar <italic>et al</italic>. 2009</xref>]. Recent evidence showing that estrogen might promote angiogenesis has again sparked interest in estrogen as a potential treatment option [<xref ref-type="bibr" rid="bibr96-1753944712437359">Kyriakides <italic>et al</italic>. 2001</xref>; <xref ref-type="bibr" rid="bibr146-1753944712437359">Ruifrok <italic>et al</italic>. 2009</xref>].</p>
</sec>
<sec id="section24-1753944712437359">
<title>Pentoxifylline</title>
<p>Pentoxifylline was the first drug therapy approved for the treatment of claudication symptoms. It has only a small benefit over placebo for the improvement in walking distances [<xref ref-type="bibr" rid="bibr58-1753944712437359">Girolami <italic>et al</italic>. 1999</xref>]. Cilostazol has been proven to be more effective and has virtually replaced pentoxifylline [<xref ref-type="bibr" rid="bibr35-1753944712437359">Dawson <italic>et al</italic>. 2000</xref>]. It can be used in people with severe claudication symptoms who have contraindications to cilostazol.</p>
</sec>
<sec id="section25-1753944712437359">
<title>Naftidrofuryl</title>
<p>Naftidrofuryl is a 5-hydroxytryptamine-2 receptor which has been shown to be more effective than placebo for improvement of claudication symptoms [<xref ref-type="bibr" rid="bibr37-1753944712437359">De Backer <italic>et al</italic>. 2009</xref>]. It has also been shown to improve cutaneous vasomotor symptoms of PAD in patients with diabetes [<xref ref-type="bibr" rid="bibr173-1753944712437359">Tretjakovs <italic>et al</italic>. 2006</xref>].</p>
</sec>
<sec id="section26-1753944712437359">
<title>Trans-sodium crocetinate</title>
<p>Trans-sodium crocetinate (TSC) is a synthetic carotenoid designed to enhance the oxygenation of hypoxic tissues. Various models have shown the increased oxygen diffusivity to be the primary mechanism of action [<xref ref-type="bibr" rid="bibr52-1753944712437359">Gainer, 2008</xref>; <xref ref-type="bibr" rid="bibr104-1753944712437359">Manabe <italic>et al</italic>. 2010</xref>]. Mohler and colleagues reported that it was a safely tolerated drug at all doses and notable benefits were observed with higher doses in terms of peak walking time and patient perceived walking distance [<xref ref-type="bibr" rid="bibr113-1753944712437359">Mohler <italic>et al</italic>. 2011</xref>].</p>
</sec>
<sec id="section27-1753944712437359">
<title>Hyperbaric oxygen therapy</title>
<p>Treatment with hyperbaric oxygen therapy has been shown to result in rapid regression of atherosclerotic plaques in animals [<xref ref-type="bibr" rid="bibr94-1753944712437359">Kudchodkar <italic>et al</italic>. 2000</xref>]. It has been shown to reduce the restenosis rate after coronary interventions [<xref ref-type="bibr" rid="bibr115-1753944712437359">Mohsen <italic>et al</italic>. 2004</xref>]. Its application in CAD and later on in PAD is an area of future research.</p>
</sec>
<sec id="section28-1753944712437359">
<title>Therapeutic angiogenesis</title>
<p>Considerable interest has developed in this means of PAD prevention. Success has been shown with recombinant fibroblast growth factor and vascular endothelial growth factor (VEGF) in improvement of claudication and critical limb ischemia, respectively [<xref ref-type="bibr" rid="bibr98-1753944712437359">Lederman <italic>et al</italic>. 2002</xref>; <xref ref-type="bibr" rid="bibr155-1753944712437359">Shyu <italic>et al</italic>. 2003</xref>]. Polydeoxyribonucleotide, which stimulates VEGF production, has recently been shown to be a safe and effective approach in patients with PAD and diabetes with ulcers [<xref ref-type="bibr" rid="bibr5-1753944712437359">Altavilla <italic>et al</italic>. 2009</xref>].</p>
</sec>
<sec id="section29-1753944712437359">
<title>Prostaglandin E1</title>
<p>Prostaglandin E1 (PGE-1) has been shown to improve quality of life in patients with PAD [<xref ref-type="bibr" rid="bibr106-1753944712437359">Matsuo and Shigematsu, 2010</xref>]. It exerts a peripheral vasodilation effect by increasing cyclic adenosine monophosphate, decreasing cellular calcium ions, and relaxing vascular smooth muscle; this may be further enhanced by improved walking. PGE-1 has also been reported to down-modulate soluble adhesion molecules involved in vascular inflammation and decrease the levels of monocyte chemoattractant protein [<xref ref-type="bibr" rid="bibr56-1753944712437359">Gianetti <italic>et al</italic>. 2001</xref>; <xref ref-type="bibr" rid="bibr105-1753944712437359">Matsui <italic>et al</italic>. 2003</xref>]. These are implicated in proatherogenic foam cell recruitment and formation. When compared with pentoxiphylline-buflomedil infusion, it was associated with significant improvements in pain-free walking distance and maximal walking distance [<xref ref-type="bibr" rid="bibr111-1753944712437359">Milio <italic>et al</italic>. 2006</xref>].</p>
</sec>
<sec id="section30-1753944712437359">
<title>Advanced glycation end products and atherosclerosis</title>
<p>AGEs are formed when a sugar molecule binds to a protein or lipid molecule without enzymatic control. They have been implicated in development of atherosclerosis and vascular aging, leading to cardiovascular disease [<xref ref-type="bibr" rid="bibr158-1753944712437359">Simm <italic>et al</italic>. 2007</xref>] and stroke [<xref ref-type="bibr" rid="bibr190-1753944712437359">Zimmerman <italic>et al</italic>. 1995</xref>]. AGEs are thought to induce damage through a process called cross linking that causes intracellular damage and apoptosis [<xref ref-type="bibr" rid="bibr154-1753944712437359">Shaikh and Nicholson, 2008</xref>]. This is currently under research and some drugs like aspirin [<xref ref-type="bibr" rid="bibr19-1753944712437359">Bucala and Cerami, 1992</xref>], benfotiamine [<xref ref-type="bibr" rid="bibr165-1753944712437359">Stirban <italic>et al</italic>. 2006</xref>] and carnosine [<xref ref-type="bibr" rid="bibr63-1753944712437359">Guiotto <italic>et al</italic>. 2005</xref>] have been shown to inhibit this process, but their role in PAD management still seems to be only of research interest. Alagebrium, also an inhibitor, showed some promise during initial research but its further evaluation could not be continued due to financial issues and is now considered to be a failed drug [<xref ref-type="bibr" rid="bibr10-1753944712437359">Bakris <italic>et al</italic>. 2004</xref>].</p>
</sec></sec>
</sec>
<sec id="section31-1753944712437359">
<title>Peripheral artery disease along with other diseases</title>
<p>There is high prevalence of CAD in patients with PAD [<xref ref-type="bibr" rid="bibr31-1753944712437359">Criqui <italic>et al</italic>. 1992</xref>; <xref ref-type="bibr" rid="bibr179-1753944712437359">Vogt <italic>et al</italic>. 1993</xref>]. All patients with PAD should be considered to be at high risk for CAD and evaluated thoroughly. Patients with signs and symptoms of CAD should be managed according to current guidelines. Patients considered for vascular surgery should be evaluated for cardiac risks and need for coronary revascularization which should not be performed routinely [<xref ref-type="bibr" rid="bibr44-1753944712437359">Eagle <italic>et al</italic>. 2002</xref>; <xref ref-type="bibr" rid="bibr125-1753944712437359">Norgren <italic>et al</italic>. 2007</xref>]. The treatment of patients with PAD and cerebrovascular disease [<xref ref-type="bibr" rid="bibr1-1753944712437359">Adams <italic>et al</italic>. 2003</xref>] or renal disease [<xref ref-type="bibr" rid="bibr132-1753944712437359">Plouin <italic>et al</italic>. 2003</xref>] should also be based on the current guidelines [<xref ref-type="bibr" rid="bibr125-1753944712437359">Norgren <italic>et al</italic>. 2007</xref>]. Thus, the management of other diseases that may coexist with PAD does not change much with the presence or absence of PAD. All these patients should be evaluated properly and referred appropriately.</p>
</sec>
<sec id="section32-1753944712437359">
<title>Financial implications</title>
<p>The total annual costs of PAD in the USA are estimated to exceed $21 billion [<xref ref-type="bibr" rid="bibr70-1753944712437359">Hirsch <italic>et al</italic>. 2008</xref>]. Complications after PAD treatment further increase this cost. Whether screening by ABI determination is cost effective is still controversial, but any clinical trial in this regard is unlikely as there is full agreement in favor of ABI use [<xref ref-type="bibr" rid="bibr124-1753944712437359">Norgren <italic>et al</italic>. 2010</xref>]. Due to higher costs associated with disability, including loss of wages and impact on the family infrastructure, this area needs further deliberation. In a cost-effectiveness analysis, ACE inhibition was associated with the largest reduction in events leading to the highest gain in quality-adjusted life years and lowest mean cost [<xref ref-type="bibr" rid="bibr156-1753944712437359">Sigvant <italic>et al</italic>. 2011</xref>]. The authors suggested that efforts should be made to identify patients with asymptomatic PAD and ACE inhibition considered for those identified.</p>
</sec>
<sec id="section33-1753944712437359" sec-type="conclusions">
<title>Conclusion</title>
<p>The prevalence of PAD is increasing at an alarming rate. The associated morbidity and mortality call for greater emphasis on prevention and early treatment. Various risk factors contribute to the development of PAD and many of these are modifiable. In the light of growing evidence, recognizing and attempting primary and secondary prevention of this disease is of utmost importance.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure"><p>This work was not supported by any funding from any source.</p></fn>
<fn fn-type="conflict"><p>The authors declare no conflicts of interest in preparing this article.</p></fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Adams</surname><given-names>R.J.</given-names></name>
<name><surname>Chimowitz</surname><given-names>M.I.</given-names></name>
<name><surname>Alpert</surname><given-names>J.S.</given-names></name>
<name><surname>Awad</surname><given-names>I.A.</given-names></name>
<name><surname>Cerqueria</surname><given-names>M.D.</given-names></name>
<name><surname>Fayad</surname><given-names>P.</given-names></name>
<etal/>
</person-group>. (<year>2003</year>) <article-title>Coronary risk evaluation in patients with transient ischemic attack and ischemic stroke: a scientific statement for healthcare professionals from the Stroke Council and the Council on Clinical Cardiology of the American Heart Association/American Stroke Association</article-title>. <source>Circulation</source> <volume>108</volume>: <fpage>1278</fpage>–<lpage>1290</lpage>.</citation>
</ref>
<ref id="bibr2-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Aguilar</surname><given-names>E.M.</given-names></name>
<name><surname>Miralles</surname><given-names>J.D.H.</given-names></name>
<name><surname>Gonzlez</surname><given-names>A.F.</given-names></name>
<name><surname>Casariego</surname><given-names>C.V.</given-names></name>
<name><surname>Moreno</surname><given-names>S.B.</given-names></name>
<name><surname>Garca</surname><given-names>F.A.</given-names></name>
</person-group> (<year>2009</year>) <article-title>In vivo confirmation of the role of statins in reducing nitric oxide and C-reactive protein levels in peripheral arterial disease</article-title>. <source>Eur J Vasc Endovasc Surg</source> <volume>37</volume>: <fpage>443</fpage>–<lpage>447</lpage>.</citation>
</ref>
<ref id="bibr3-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ajayi</surname><given-names>A.A.</given-names></name>
<name><surname>Campbell</surname><given-names>B.C.</given-names></name>
<name><surname>Howie</surname><given-names>C.A.</given-names></name>
<name><surname>Reid</surname><given-names>J.L.</given-names></name>
</person-group> (<year>1985</year>) <article-title>Acute and chronic effects of the converting enzyme inhibitors enalapril and lisinopril on reflex control of heart rate in normotensive man</article-title>. <source>J Hypertens</source> <volume>3</volume>: <fpage>47</fpage>–<lpage>53</lpage>.</citation>
</ref>
<ref id="bibr4-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Alain</surname><given-names>C.T.</given-names></name>
<name><surname>Patrik</surname><given-names>M.</given-names></name>
<name><surname>Juerg</surname><given-names>N.</given-names></name>
<name><surname>Robert</surname><given-names>S.</given-names></name>
<name><surname>Thomas</surname><given-names>P.</given-names></name>
<name><surname>Stanislav</surname><given-names>I.</given-names></name>
<etal/>
</person-group>. (<year>2008</year>) <article-title>Effect of immunisation against angiotensin Ii with CYT006-AngQb on ambulatory blood pressure: a double- blind, randomised, placebo-controlled phase IIa study</article-title>. <source>Lancet</source> <volume>371</volume>: <fpage>821</fpage>–<lpage>827</lpage>.</citation>
</ref>
<ref id="bibr5-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Altavilla</surname><given-names>D.</given-names></name>
<name><surname>Bitto</surname><given-names>A.</given-names></name>
<name><surname>Polito</surname><given-names>F.</given-names></name>
<name><surname>Marini</surname><given-names>H.</given-names></name>
<name><surname>Minutoli</surname><given-names>L.</given-names></name>
<name><surname>Di Stefano</surname><given-names>V.</given-names></name>
<etal/>
</person-group>. (<year>2009</year>) <article-title>Polydeoxyribonucleotide (PDRN): a safe approach to induce therapeutic angiogenesis in peripheral artery occlusive disease and in diabetic foot ulcers</article-title>. <source>Cardiovasc Hematol Agents Med Chem</source> <volume>7</volume>: <fpage>313</fpage>–<lpage>321</lpage>.</citation>
</ref>
<ref id="bibr6-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ameli</surname><given-names>F.</given-names></name>
<name><surname>Stein</surname><given-names>M.</given-names></name>
<name><surname>Provan</surname><given-names>J.</given-names></name>
<name><surname>Prosser</surname><given-names>R.</given-names></name>
</person-group> (<year>1989</year>) <article-title>The effect of postoperative smoking on femoropopliteal bypass grafts</article-title>. <source>Ann Vasc Surg</source> <volume>3</volume>: <fpage>20</fpage>–<lpage>25</lpage>.</citation>
</ref>
<ref id="bibr7-1753944712437359">
<citation citation-type="journal">
<collab>American Diabetes Association</collab> (<year>2010</year>) <article-title>Standards of medical care in diabetes – 2010</article-title>. <source>Diabetes Care</source> <volume>33</volume>: <fpage>S11</fpage>–<lpage>S61</lpage>.</citation>
</ref>
<ref id="bibr8-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Anand</surname><given-names>S.</given-names></name>
<name><surname>Yusuf</surname><given-names>S.</given-names></name>
<name><surname>Xie</surname><given-names>C.</given-names></name>
<name><surname>Pogue</surname><given-names>J.</given-names></name>
<name><surname>Eikelboom</surname><given-names>J.</given-names></name>
<name><surname>Budaj</surname><given-names>A.</given-names></name>
<etal/>
</person-group>. (<year>2007</year>) <article-title>Oral anticoagulant and antiplatelet therapy and peripheral arterial disease</article-title>. <source>N Engl J Med</source> <volume>357</volume>: <fpage>217</fpage>–<lpage>227</lpage>.</citation>
</ref>
<ref id="bibr9-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Appel</surname><given-names>L.J.</given-names></name>
<name><surname>Espeland</surname><given-names>M.A.</given-names></name>
<name><surname>Easter</surname><given-names>L.</given-names></name>
<name><surname>Wilson</surname><given-names>A.C.</given-names></name>
<name><surname>Folmar</surname><given-names>S.</given-names></name>
<name><surname>Lacy</surname><given-names>C.R.</given-names></name>
</person-group> (<year>2001</year>) <article-title>Effects of reduced sodium intake on hypertension control in older individuals: results from the Trial of Nonpharmacologic Interventions in the Elderly (TONE)</article-title>. <source>Arch Intern Med</source> <volume>161</volume>: <fpage>685</fpage>–<lpage>693</lpage>.</citation>
</ref>
<ref id="bibr10-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bakris</surname><given-names>G.L.</given-names></name>
<name><surname>Bank</surname><given-names>A.J.</given-names></name>
<name><surname>Kass</surname><given-names>D.A.</given-names></name>
<name><surname>Neutel</surname><given-names>J.M.</given-names></name>
<name><surname>Preston</surname><given-names>R.A.</given-names></name>
<name><surname>Oparil</surname><given-names>S.</given-names></name>
</person-group> (<year>2004</year>) <article-title>Advanced glycation end-product cross-link breakers. A novel approach to cardiovascular pathologies related to the aging process</article-title>. <source>Am J Hypertens</source> <volume>17</volume>: <fpage>23S</fpage>–<lpage>30S</lpage>.</citation>
</ref>
<ref id="bibr11-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Balsano</surname><given-names>F.</given-names></name>
<name><surname>Violi</surname><given-names>F.</given-names></name>
</person-group> (<year>1993</year>) <article-title>Effect of picotamide on the clinical progression of peripheral vascular disease. A double-blind placebo-controlled study. The ADEP Group</article-title>. <source>Circulation</source> <volume>87</volume>: <fpage>1563</fpage>–<lpage>1569</lpage>.</citation>
</ref>
<ref id="bibr12-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Basili</surname><given-names>S.</given-names></name>
<name><surname>Raparelli</surname><given-names>V.</given-names></name>
<name><surname>Vestri</surname><given-names>A.</given-names></name>
<name><surname>Di Tanna</surname><given-names>G.L.</given-names></name>
<name><surname>Violi</surname><given-names>F.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Comparison of efficacy of antiplatelet treatments for patients with claudication. a meta-analysis</article-title>. <source>Thromb Haemost</source> <volume>103</volume>: <fpage>766</fpage>–<lpage>773</lpage>.</citation>
</ref>
<ref id="bibr13-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bhatt</surname><given-names>D.L.</given-names></name>
<name><surname>Bertrand</surname><given-names>M.E.</given-names></name>
<name><surname>Berger</surname><given-names>P.B.</given-names></name>
<name><surname>L’Allier</surname><given-names>P.L.</given-names></name>
<name><surname>Moussa</surname><given-names>I.</given-names></name>
<name><surname>Moses</surname><given-names>J.W.</given-names></name>
<etal/>
</person-group>. (<year>2002</year>) <article-title>Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting</article-title>. <source>J Am Coll Cardiol</source> <volume>39</volume>: <fpage>9</fpage>–<lpage>14</lpage>.</citation>
</ref>
<ref id="bibr14-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bhatt</surname><given-names>D.</given-names></name>
<name><surname>Fox</surname><given-names>K.</given-names></name>
<name><surname>Werner Hacke</surname><given-names>C.</given-names></name>
<name><surname>Berger</surname><given-names>P.</given-names></name>
<name><surname>Black</surname><given-names>H.</given-names></name>
<name><surname>Boden</surname><given-names>W.</given-names></name>
<etal/>
</person-group>. (<year>2006</year>) <article-title>Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events</article-title>. <source>New Eng J Med</source> <volume>354</volume>: <fpage>1706</fpage>–<lpage>1717</lpage>.</citation>
</ref>
<ref id="bibr15-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bhatt</surname><given-names>D.L.</given-names></name>
<name><surname>Hirsch</surname><given-names>A.T.</given-names></name>
<name><surname>Ringleb</surname><given-names>P.A.</given-names></name>
<name><surname>Hacke</surname><given-names>W.</given-names></name>
<name><surname>Topol</surname><given-names>E.J.</given-names></name>
</person-group> (<year>2000</year>) <article-title>Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin. Caprie Investigators</article-title>. <source>Am Heart J</source> <volume>140</volume>: <fpage>67</fpage>–<lpage>73</lpage>.</citation>
</ref>
<ref id="bibr16-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bolinder</surname><given-names>G.</given-names></name>
<name><surname>Alfredsson</surname><given-names>L.</given-names></name>
<name><surname>Englund</surname><given-names>A.</given-names></name>
<name><surname>De Faire</surname><given-names>U.</given-names></name>
</person-group> (<year>1994</year>) <article-title>Smokeless tobacco use and increased cardiovascular mortality among Swedish construction workers</article-title>. <source>Am J Public Health</source> <volume>84</volume>: <fpage>399</fpage>–<lpage>404</lpage>.</citation>
</ref>
<ref id="bibr17-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bonaa</surname><given-names>K.H.</given-names></name>
<name><surname>Njolstad</surname><given-names>I.</given-names></name>
<name><surname>Ueland</surname><given-names>P.M.</given-names></name>
<name><surname>Schirmer</surname><given-names>H.</given-names></name>
<name><surname>Tverdal</surname><given-names>A.</given-names></name>
<name><surname>Steigen</surname><given-names>T.</given-names></name>
<etal/>
</person-group>. (<year>2006</year>) <article-title>Homocysteine lowering and cardiovascular events after acute myocardial infarction</article-title>. <source>N Engl J Med</source> <volume>354</volume>: <fpage>1578</fpage>–<lpage>1588</lpage>.</citation>
</ref>
<ref id="bibr18-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Boushey</surname><given-names>C.J.</given-names></name>
<name><surname>Beresford</surname><given-names>S.A.</given-names></name>
<name><surname>Omenn</surname><given-names>G.S.</given-names></name>
<name><surname>Motulsky</surname><given-names>A.G.</given-names></name>
</person-group> (<year>1995</year>) <article-title>A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes</article-title>. <source>JAMA</source> <volume>274</volume>: <fpage>1049</fpage>–<lpage>1057</lpage>.</citation>
</ref>
<ref id="bibr19-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bucala</surname><given-names>R.</given-names></name>
<name><surname>Cerami</surname><given-names>A.</given-names></name>
</person-group> (<year>1992</year>) <article-title>Advanced glycosylation: chemistry, biology, and implications for diabetes and aging</article-title>. <source>Adv Pharmacol</source> <volume>23</volume>: <fpage>1</fpage>–<lpage>34</lpage>.</citation>
</ref>
<ref id="bibr20-1753944712437359">
<citation citation-type="journal">
<collab>Bypass Angioplasty Revascularization Investigation Investigators</collab> (<year>1996</year>) <article-title>Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease</article-title>. <source>N Engl J Med</source> <volume>335</volume>: <fpage>217</fpage>–<lpage>225</lpage>.</citation>
</ref>
<ref id="bibr21-1753944712437359">
<citation citation-type="journal">
<collab>CAPRIE Steering Committee</collab> (<year>1996</year>) <article-title>A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)</article-title>. <source>The Lancet</source> <volume>348</volume>: <fpage>1329</fpage>–<lpage>1339</lpage>.</citation>
</ref>
<ref id="bibr22-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cefali</surname><given-names>E.A.</given-names></name>
<name><surname>Simmons</surname><given-names>P.D.</given-names></name>
<name><surname>Stanek</surname><given-names>E.J.</given-names></name>
<name><surname>McGovern</surname><given-names>M.E.</given-names></name>
<name><surname>Kissling</surname><given-names>C.J.</given-names></name>
</person-group> (<year>2007</year>) <article-title>Aspirin reduces cutaneous flushing after administration of an optimized extended-release niacin formulation</article-title>. <source>Int J Clin Pharmacol Ther</source> <volume>45</volume>: <fpage>78</fpage>–<lpage>88</lpage>.</citation>
</ref>
<ref id="bibr23-1753944712437359">
<citation citation-type="journal">
<collab>Centers for Disease Control and Prevention</collab> (<year>2001</year>) <article-title>Hospital discharge rates for nontraumatic lower extremity amputation by diabetes status – United States, 1997</article-title>. <source>MMWR Morb Mortal Wkly Rep</source> <volume>50</volume>: <fpage>954</fpage>–<lpage>958</lpage>.</citation>
</ref>
<ref id="bibr24-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chobanian</surname><given-names>A.V.</given-names></name>
<name><surname>Bakris</surname><given-names>G.L.</given-names></name>
<name><surname>Black</surname><given-names>H.R.</given-names></name>
<name><surname>Cushman</surname><given-names>W.C.</given-names></name>
<name><surname>Green</surname><given-names>L.A.</given-names></name>
<name><surname>Izzo</surname><given-names>J.L.</given-names><suffix>Jr</suffix></name>
<etal/>
</person-group>. (<year>2003</year>) <article-title>Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure</article-title>. <source>Hypertension</source> <volume>42</volume>: <fpage>1206</fpage>–<lpage>1252</lpage>.</citation>
</ref>
<ref id="bibr25-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Clagett</surname><given-names>G.P.</given-names></name>
<name><surname>Sobel</surname><given-names>M.</given-names></name>
<name><surname>Jackson</surname><given-names>M.R.</given-names></name>
<name><surname>Lip</surname><given-names>G.Y.</given-names></name>
<name><surname>Tangelder</surname><given-names>M.</given-names></name>
<name><surname>Verhaeghe</surname><given-names>R.</given-names></name>
</person-group> (<year>2004</year>) <article-title>Antithrombotic therapy in peripheral arterial occlusive disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy</article-title>. <source>Chest</source> <volume>126</volume>: <fpage>609S</fpage>–<lpage>626S</lpage>.</citation>
</ref>
<ref id="bibr26-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Clowes</surname><given-names>A.W.</given-names></name>
<name><surname>Reidy</surname><given-names>M.A.</given-names></name>
<name><surname>Clowes</surname><given-names>M.M.</given-names></name>
</person-group> (<year>1983</year>) <article-title>Kinetics of cellular proliferation after arterial injury. I. Smooth muscle growth in the absence of endothelium</article-title>. <source>Lab Invest</source> <volume>49</volume>: <fpage>327</fpage>–<lpage>333</lpage>.</citation>
</ref>
<ref id="bibr27-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Clyne</surname><given-names>C.A.</given-names></name>
<name><surname>Archer</surname><given-names>T.J.</given-names></name>
<name><surname>Atuhaire</surname><given-names>L.K.</given-names></name>
<name><surname>Chant</surname><given-names>A.D.B.</given-names></name>
<name><surname>Webster</surname><given-names>J.H.H.</given-names></name>
</person-group> (<year>1987</year>) <article-title>Random control trial of a short course of aspirin and dipyridamole (Persantin) for femorodistal grafts</article-title>. <source>Br J Surg</source> <volume>74</volume>: <fpage>246</fpage>–<lpage>248</lpage>.</citation>
</ref>
<ref id="bibr28-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Craig</surname><given-names>M.P.</given-names></name>
</person-group> (<year>2001</year>) <article-title>Analysis of the cilostazol safety database</article-title>. <source>Am J Cardiol</source> <volume>87</volume>: <fpage>28</fpage>–<lpage>33</lpage>.</citation>
</ref>
<ref id="bibr29-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Criqui</surname><given-names>M.H.</given-names></name>
</person-group> (<year>2001</year>) <article-title>Peripheral arterial disease – epidemiological aspects</article-title>. <source>Vasc Med</source> <volume>6</volume>: <fpage>3</fpage>–<lpage>7</lpage>.</citation>
</ref>
<ref id="bibr30-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Criqui</surname><given-names>M.</given-names></name>
<name><surname>Ho</surname><given-names>L.</given-names></name>
<name><surname>Denenberg</surname><given-names>J.</given-names></name>
<name><surname>Ridker</surname><given-names>P.</given-names></name>
<name><surname>Wassel</surname><given-names>C.</given-names></name>
<name><surname>Mcdermott</surname><given-names>M.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Biomarkers in peripheral arterial disease patients and near- and longer-term mortality</article-title>. <source>J Vasc Surg</source> <volume>52</volume>: <fpage>85</fpage>–<lpage>90</lpage>.</citation>
</ref>
<ref id="bibr31-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Criqui</surname><given-names>M.H.</given-names></name>
<name><surname>Langer</surname><given-names>R.D.</given-names></name>
<name><surname>Fronek</surname><given-names>A.</given-names></name>
<name><surname>Feigelson</surname><given-names>H.S.</given-names></name>
<name><surname>Klauber</surname><given-names>M.R.</given-names></name>
<name><surname>McCann</surname><given-names>T.J.</given-names></name>
<etal/>
</person-group>. (<year>1992</year>) <article-title>Mortality over a period of 10 years in patients with peripheral arterial disease</article-title>. <source>N Engl J Med</source> <volume>326</volume>: <fpage>381</fpage>–<lpage>386</lpage>.</citation>
</ref>
<ref id="bibr32-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dagenais</surname><given-names>G.R.</given-names></name>
<name><surname>Maurice</surname><given-names>S.</given-names></name>
<name><surname>Robitaille</surname><given-names>N.M.</given-names></name>
<name><surname>Gingras</surname><given-names>S.</given-names></name>
<name><surname>Lupien</surname><given-names>P.J.</given-names></name>
</person-group> (<year>1991</year>) <article-title>Intermittent claudication in Quebec men from 1974–1986: The Quebec Cardiovascular Study</article-title>. <source>Clin Invest Med</source> <volume>14</volume>: <fpage>93</fpage>–<lpage>100</lpage>.</citation>
</ref>
<ref id="bibr33-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Davidson</surname><given-names>M.H.</given-names></name>
</person-group> (<year>2007</year>) <article-title>Squalene synthase inhibition: a novel target for the management of dyslipidemia</article-title>. <source>Curr Atheroscler Rep</source> <volume>9</volume>: <fpage>78</fpage>–<lpage>80</lpage>.</citation>
</ref>
<ref id="bibr34-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Davidson</surname><given-names>M.H.</given-names></name>
<name><surname>Mckenney</surname><given-names>J.M.</given-names></name>
<name><surname>Shear</surname><given-names>C.L.</given-names></name>
<name><surname>Revkin</surname><given-names>J.H.</given-names></name>
</person-group> (<year>2006</year>) <article-title>Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels</article-title>. <source>J Am Coll Cardiol</source> <volume>48</volume>: <fpage>1774</fpage>–<lpage>1781</lpage>.</citation>
</ref>
<ref id="bibr35-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dawson</surname><given-names>D.L.</given-names></name>
<name><surname>Cutler</surname><given-names>B.S.</given-names></name>
<name><surname>Hiatt</surname><given-names>W.R.</given-names></name>
<name><surname>Hobson</surname><given-names>R.W.</given-names><suffix>2nd</suffix></name>
<name><surname>Martin</surname><given-names>J.D.</given-names></name>
<name><surname>Bortey</surname><given-names>E.B.</given-names></name>
<etal/>
</person-group>. (<year>2000</year>) <article-title>A comparison of cilostazol and pentoxifylline for treating intermittent claudication</article-title>. <source>Am J Med</source> <volume>109</volume>: <fpage>523</fpage>–<lpage>530</lpage>.</citation>
</ref>
<ref id="bibr36-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dawson</surname><given-names>D.L.</given-names></name>
<name><surname>Cutler</surname><given-names>B.S.</given-names></name>
<name><surname>Meissner</surname><given-names>M.H.</given-names></name>
<name><surname>Strandness</surname><given-names>D.E.</given-names><suffix>Jr</suffix></name>
</person-group> (<year>1998</year>) <article-title>Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial</article-title>. <source>Circulation</source> <volume>98</volume>: <fpage>678</fpage>–<lpage>686</lpage>.</citation>
</ref>
<ref id="bibr37-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>De Backer</surname><given-names>T.</given-names></name>
<name><surname>Vander Stichele</surname><given-names>R.</given-names></name>
<name><surname>Lehert</surname><given-names>P.</given-names></name>
<name><surname>Van Bortel</surname><given-names>L.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Naftidrofuryl for intermittent claudication: meta-analysis based on individual patient data</article-title>. <source>BMJ</source> <volume>338</volume>: <fpage>b603</fpage>.</citation>
</ref>
<ref id="bibr38-1753944712437359">
<citation citation-type="journal">
<collab>Diabetes Control and Complications Trial</collab> (<year>1995</year>) <article-title>Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial</article-title>. <source>Am J Cardiol</source> <volume>75</volume>: <fpage>894</fpage>–<lpage>903</lpage>.</citation>
</ref>
<ref id="bibr39-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Donnelly</surname><given-names>R.</given-names></name>
<name><surname>Emslie-Smith</surname><given-names>A.M.</given-names></name>
<name><surname>Gardner</surname><given-names>I.D.</given-names></name>
<name><surname>Morris</surname><given-names>A.D.</given-names></name>
</person-group> (<year>2000</year>) <article-title>Vascular complications of diabetes</article-title>. <source>BMJ</source> <volume>320</volume>: <fpage>1062</fpage>–<lpage>1066</lpage>.</citation>
</ref>
<ref id="bibr40-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dormandy</surname><given-names>J.A.</given-names></name>
<name><surname>Charbonnel</surname><given-names>B.</given-names></name>
<name><surname>Eckland</surname><given-names>D.J.</given-names></name>
<name><surname>Erdmann</surname><given-names>E.</given-names></name>
<name><surname>Massi-Benedetti</surname><given-names>M.</given-names></name>
<name><surname>Moules</surname><given-names>I.K.</given-names></name>
<etal/>
</person-group>. (<year>2005</year>) <article-title>Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (Prospective Pioglitazone Clinical Trial in Macrovascular Events): a randomised controlled trial</article-title>. <source>Lancet</source> <volume>366</volume>: <fpage>1279</fpage>–<lpage>1289</lpage>.</citation>
</ref>
<ref id="bibr41-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Douglas</surname><given-names>B.W.</given-names></name>
<name><surname>Anthony</surname><given-names>J.C.</given-names></name>
<name><surname>Frank</surname><given-names>A.S.</given-names></name>
<name><surname>Richard</surname><given-names>C.T.</given-names></name>
<name><surname>John</surname><given-names>P.G.</given-names></name>
<name><surname>Rao</surname><given-names>A.K.</given-names></name>
</person-group> (<year>2003</year>) <article-title>Managing PAD with multiple platelet inhibitors: the effect of combination therapy on bleeding time</article-title>. <source>J Vasc Surg</source> <volume>38</volume>: <fpage>710</fpage>–<lpage>713</lpage>.</citation>
</ref>
<ref id="bibr42-1753944712437359">
<citation citation-type="journal">
<collab>Dutch Bypass Oral Anticoagulants or Aspirin Study</collab> (<year>2000</year>) <article-title>Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (the Dutch Bypass Oral Anticoagulants or Aspirin Study): a randomised trial</article-title>. <source>The Lancet</source> <volume>355</volume>: <fpage>346</fpage>–<lpage>351</lpage>.</citation>
</ref>
<ref id="bibr43-1753944712437359">
<citation citation-type="journal">
<collab>Dutch TIA Trial Study Group</collab> (<year>1991</year>) <article-title>A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke</article-title>. <source>N Engl J Med</source> <volume>325</volume>: <fpage>1261</fpage>–<lpage>1266</lpage>.</citation>
</ref>
<ref id="bibr44-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Eagle</surname><given-names>K.A.</given-names></name>
<name><surname>Berger</surname><given-names>P.B.</given-names></name>
<name><surname>Calkins</surname><given-names>H.</given-names></name>
<name><surname>Chaitman</surname><given-names>B.R.</given-names></name>
<name><surname>Ewy</surname><given-names>G.A.</given-names></name>
<name><surname>Fleischmann</surname><given-names>K.E.</given-names></name>
<etal/>
</person-group>. (<year>2002</year>) <article-title>ACC/AHA guideline update for perioperative cardiovascular evaluation for noncardiac surgery – executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee to update the 1996 guidelines on perioperative cardiovascular evaluation for noncardiac surgery)</article-title>. <source>J Am Coll Cardiol</source> <volume>39</volume>: <fpage>542</fpage>–<lpage>553</lpage>.</citation>
</ref>
<ref id="bibr45-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ebbert</surname><given-names>J.O.</given-names></name>
<name><surname>Burke</surname><given-names>M.V.</given-names></name>
<name><surname>Hays</surname><given-names>J.T.</given-names></name>
<name><surname>Hurt</surname><given-names>R.D.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Combination treatment with varenicline and nicotine replacement therapy</article-title>. <source>Nicotine Tob Res</source> <volume>11</volume>: <fpage>572</fpage>–<lpage>576</lpage>.</citation>
</ref>
<ref id="bibr46-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Eissenberg</surname><given-names>T.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Electronic nicotine delivery devices: ineffective nicotine delivery and craving suppression after acute administration</article-title>. <source>Tob Control</source> <volume>19</volume>: <fpage>87</fpage>-<lpage>88</lpage>.</citation>
</ref>
<ref id="bibr47-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Elam</surname><given-names>M.B.</given-names></name>
<name><surname>Heckman</surname><given-names>J.</given-names></name>
<name><surname>Crouse</surname><given-names>J.R.</given-names></name>
<name><surname>Hunninghake</surname><given-names>D.B.</given-names></name>
<name><surname>Herd</surname><given-names>J.A.</given-names></name>
<name><surname>Davidson</surname><given-names>M.</given-names></name>
<etal/>
</person-group>. (<year>1998</year>) <article-title>Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication</article-title>. <source>Arterioscler Thromb Vasc Biol</source> <volume>18</volume>: <fpage>1942</fpage>–<lpage>1947</lpage>.</citation>
</ref>
<ref id="bibr48-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Elam</surname><given-names>M.B.</given-names></name>
<name><surname>Hunninghake</surname><given-names>D.B.</given-names></name>
<name><surname>Davis</surname><given-names>K.B.</given-names></name>
<name><surname>Garg</surname><given-names>R.</given-names></name>
<name><surname>Johnson</surname><given-names>C.</given-names></name>
<name><surname>Egan</surname><given-names>D.</given-names></name>
<etal/>
</person-group>. (<year>2000</year>) <article-title>Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease</article-title>. <source>JAMA</source> <volume>284</volume>: <fpage>1263</fpage>–<lpage>1270</lpage>.</citation>
</ref>
<ref id="bibr49-1753944712437359">
<citation citation-type="journal">
<collab>ESPRIT Study Group</collab> (<year>2006</year>) <article-title>Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial</article-title>. <source>The Lancet</source> <volume>367</volume>: <fpage>1665</fpage>–<lpage>1673</lpage>.</citation>
</ref>
<ref id="bibr50-1753944712437359">
<citation citation-type="journal">
<collab>European Society of Hypertension–European Society of Cardiology</collab> (<year>2003</year>) <year>2003</year> European Society of Hypertension–European Society of Cardiology guidelines for the management of arterial hypertension. <source>J Hypertens</source> <volume>21</volume>: <fpage>1011</fpage>–<lpage>1053</lpage>.</citation>
</ref>
<ref id="bibr51-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fowkes</surname><given-names>F.G.</given-names></name>
<name><surname>Housley</surname><given-names>E.</given-names></name>
<name><surname>Riemersma</surname><given-names>R.A.</given-names></name>
<name><surname>Macintyre</surname><given-names>C.C.</given-names></name>
<name><surname>Cawood</surname><given-names>E.H.</given-names></name>
<name><surname>Prescott</surname><given-names>R.J.</given-names></name>
<etal/>
</person-group>. (<year>1992</year>) <article-title>Smoking, lipids, glucose intolerance, and blood pressure as risk factors for peripheral atherosclerosis compared with ischemic heart disease in the Edinburgh Artery Study</article-title>. <source>Am J Epidemiol</source> <volume>135</volume>: <fpage>331</fpage>–<lpage>340</lpage>.</citation>
</ref>
<ref id="bibr52-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gainer</surname><given-names>J.L.</given-names></name>
</person-group> (<year>2008</year>) <article-title>Trans-sodium crocetinate for treating hypoxia/ischemia</article-title>. <source>Expert Opin Investig Drugs</source> <volume>17</volume>: <fpage>917</fpage>–<lpage>924</lpage>.</citation>
</ref>
<ref id="bibr53-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gardner</surname><given-names>A.W.</given-names></name>
<name><surname>Poehlman</surname><given-names>E.T.</given-names></name>
</person-group> (<year>1995</year>) <article-title>Exercise rehabilitation programs for the treatment of claudication pain. A meta-analysis</article-title>. <source>JAMA</source> <volume>274</volume>: <fpage>975</fpage>–<lpage>980</lpage>.</citation>
</ref>
<ref id="bibr54-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gary</surname><given-names>T.</given-names></name>
<name><surname>Rief</surname><given-names>P.</given-names></name>
<name><surname>Stojakovic</surname><given-names>T.</given-names></name>
<name><surname>Froehlich</surname><given-names>H.</given-names></name>
<name><surname>Scharnagl</surname><given-names>H.</given-names></name>
<name><surname>Hafner</surname><given-names>F.</given-names></name>
<etal/>
</person-group>. (<year>2010</year>) <article-title>Lipoproteins and the development of restenosis after stent implantation in the superficial femoral artery in patients with peripheral artery disease</article-title>. <source>Cardiovasc Intervent Radiol</source> <volume>34</volume>: <fpage>739</fpage>–<lpage>743</lpage>.</citation>
</ref>
<ref id="bibr55-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Geeganage</surname><given-names>C.</given-names></name>
<name><surname>Wilcox</surname><given-names>R.</given-names></name>
<name><surname>Bath</surname><given-names>P.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Triple antiplatelet therapy for preventing vascular events: a systematic review and meta-analysis</article-title>. <source>BMC Med</source> <volume>8</volume>: <fpage>36</fpage>.</citation>
</ref>
<ref id="bibr56-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gianetti</surname><given-names>J.</given-names></name>
<name><surname>De Caterina</surname><given-names>M.</given-names></name>
<name><surname>De Cristofaro</surname><given-names>T.</given-names></name>
<name><surname>Ungaro</surname><given-names>B.</given-names></name>
<name><surname>Guercio</surname><given-names>R.D.</given-names></name>
<name><surname>De Caterina</surname><given-names>R.</given-names></name>
</person-group> (<year>2001</year>) <article-title>Intravenous prostaglandin e1 reduces soluble vascular cell adhesion molecule-1 in peripheral arterial obstructive disease</article-title>. <source>Am Heart J</source> <volume>142</volume>: <fpage>733</fpage>–<lpage>739</lpage>.</citation>
</ref>
<ref id="bibr57-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Giansante</surname><given-names>C.</given-names></name>
<name><surname>Calabrese</surname><given-names>S.</given-names></name>
<name><surname>Fisicaro</surname><given-names>M.</given-names></name>
<name><surname>Fiotti</surname><given-names>N.</given-names></name>
<name><surname>Mitri</surname><given-names>E.</given-names></name>
</person-group> (<year>1990</year>) <article-title>Treatment of intermittent claudication with antiplatelet agents</article-title>. <source>J Int Med Res</source> <volume>18</volume>: <fpage>400</fpage>–<lpage>407</lpage>.</citation>
</ref>
<ref id="bibr58-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Girolami</surname><given-names>B.</given-names></name>
<name><surname>Bernardi</surname><given-names>E.</given-names></name>
<name><surname>Prins</surname><given-names>M.H.</given-names></name>
<name><surname>Ten Cate</surname><given-names>J.W.</given-names></name>
<name><surname>Hettiarachchi</surname><given-names>R.</given-names></name>
<name><surname>Prandoni</surname><given-names>P.</given-names></name>
<etal/>
</person-group>. (<year>1999</year>) <article-title>Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta-analysis</article-title>. <source>Arch Intern Med</source> <volume>159</volume>: <fpage>337</fpage>–<lpage>345</lpage>.</citation>
</ref>
<ref id="bibr59-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gofrit</surname><given-names>O.N.</given-names></name>
<name><surname>Shemer</surname><given-names>J.</given-names></name>
<name><surname>Leibovici</surname><given-names>D.</given-names></name>
<name><surname>Modan</surname><given-names>B.</given-names></name>
<name><surname>Shapira</surname><given-names>S.C.</given-names></name>
</person-group> (<year>2000</year>) <article-title>Quaternary prevention: a new look at an old challenge</article-title>. <source>Isr Med Assoc J</source> <volume>2</volume>: <fpage>498</fpage>–<lpage>500</lpage>.</citation>
</ref>
<ref id="bibr60-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Goldhaber</surname><given-names>S.Z.</given-names></name>
<name><surname>Manson</surname><given-names>J.E.</given-names></name>
<name><surname>Stampfer</surname><given-names>M.J.</given-names></name>
<name><surname>Lamotte</surname><given-names>F.</given-names></name>
<name><surname>Rosner</surname><given-names>B.</given-names></name>
<name><surname>Buring</surname><given-names>J.E.</given-names></name>
<etal/>
</person-group>. (<year>1992</year>) <article-title>Low-dose aspirin and subsequent peripheral arterial surgery in the Physicians’ Health Study</article-title>. <source>The Lancet</source> <volume>340</volume>: <fpage>143</fpage>–<lpage>145</lpage>.</citation>
</ref>
<ref id="bibr61-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gorelick</surname><given-names>P.B.</given-names></name>
<name><surname>Born</surname><given-names>G.V.</given-names></name>
<name><surname>D’Agostino</surname><given-names>R.B.</given-names></name>
<name><surname>Hanley</surname><given-names>D.F.</given-names><suffix>Jr</suffix></name>
<name><surname>Moye</surname><given-names>L.</given-names></name>
<name><surname>Pepine</surname><given-names>C.J.</given-names></name>
</person-group> (<year>1999</year>) <article-title>Therapeutic benefit. Aspirin revisited in light of the introduction of clopidogrel</article-title>. <source>Stroke</source> <volume>30</volume>: <fpage>1716</fpage>–<lpage>1721</lpage>.</citation>
</ref>
<ref id="bibr62-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Green</surname><given-names>A.</given-names></name>
<name><surname>Yancy</surname><given-names>W.S.</given-names></name>
<name><surname>Braxton</surname><given-names>L.</given-names></name>
<name><surname>Westman</surname><given-names>E.C.</given-names></name>
</person-group> (<year>2003</year>) <article-title>Residential smoking therapy</article-title>. <source>J Gen Intern Med</source> <volume>18</volume>: <fpage>275</fpage>–<lpage>280</lpage>.</citation>
</ref>
<ref id="bibr63-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Guiotto</surname><given-names>A.</given-names></name>
<name><surname>Calderan</surname><given-names>A.</given-names></name>
<name><surname>Ruzza</surname><given-names>P.</given-names></name>
<name><surname>Borin</surname><given-names>G.</given-names></name>
</person-group> (<year>2005</year>) <article-title>Carnosine and carnosine-related antioxidants: a review</article-title>. <source>Curr Med Chem</source> <volume>12</volume>: <fpage>2293</fpage>–<lpage>2315</lpage>.</citation>
</ref>
<ref id="bibr64-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gunnell</surname><given-names>D.</given-names></name>
<name><surname>Irvine</surname><given-names>D.</given-names></name>
<name><surname>Wise</surname><given-names>L.</given-names></name>
<name><surname>Davies</surname><given-names>C.</given-names></name>
<name><surname>Martin</surname><given-names>R.M.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Varenicline and suicidal behaviour: a cohort study based on data from the General Practice Research Database</article-title>. <source>BMJ</source> <volume>339</volume>: <fpage>b3805</fpage>.</citation>
</ref>
<ref id="bibr65-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hall</surname><given-names>S.</given-names></name>
<name><surname>Humfleet</surname><given-names>G.</given-names></name>
<name><surname>Reus</surname><given-names>V.</given-names></name>
<name><surname>Munoz</surname><given-names>R.</given-names></name>
<name><surname>Hartz</surname><given-names>D.</given-names></name>
<name><surname>Maude-Griffin</surname><given-names>R.</given-names></name>
</person-group> (<year>2002</year>) <article-title>Psychological intervention and antidepressant treatment in smoking cessation</article-title>. <source>Arch Gen Psychiatry</source> <volume>59</volume>: <fpage>930</fpage>–<lpage>936</lpage>.</citation>
</ref>
<ref id="bibr66-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hansson</surname><given-names>L.</given-names></name>
<name><surname>Zanchetti</surname><given-names>A.</given-names></name>
<name><surname>Carruthers</surname><given-names>S.G.</given-names></name>
<name><surname>Dahlof</surname><given-names>B.</given-names></name>
<name><surname>Elmfeldt</surname><given-names>D.</given-names></name>
<name><surname>Julius</surname><given-names>S.</given-names></name>
<etal/>
</person-group>. (<year>1998</year>) <article-title>Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (hot) randomised trial. Hot Study Group</article-title>. <source>Lancet</source> <volume>351</volume>: <fpage>1755</fpage>–<lpage>1762</lpage>.</citation>
</ref>
<ref id="bibr67-1753944712437359">
<citation citation-type="journal">
<collab>Heart Protection Study Collaborative Group</collab> (<year>2002</year>) <article-title>MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial</article-title>. <source>Lancet</source> <volume>360</volume>: <fpage>7</fpage>–<lpage>22</lpage>.</citation>
</ref>
<ref id="bibr68-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hess</surname><given-names>H.</given-names></name>
<name><surname>Mietaschk</surname><given-names>A.</given-names></name>
<name><surname>Deichsel</surname><given-names>G.</given-names></name>
</person-group> (<year>1985</year>) <article-title>Drug-induced inhibition of platelet function delays progression of peripheral occlusive arterial disease: a prospective double-blind arteriographically controlled trial</article-title>. <source>The Lancet</source> <volume>325</volume>: <fpage>415</fpage>–<lpage>419</lpage>.</citation>
</ref>
<ref id="bibr69-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hirsch</surname><given-names>A.T.</given-names></name>
<name><surname>Criqui</surname><given-names>M.H.</given-names></name>
<name><surname>Treat-Jacobson</surname><given-names>D.</given-names></name>
<name><surname>Regensteiner</surname><given-names>J.G.</given-names></name>
<name><surname>Creager</surname><given-names>M.A.</given-names></name>
<name><surname>Olin</surname><given-names>J.W.</given-names></name>
<etal/>
</person-group>. (<year>2001</year>) <article-title>Peripheral arterial disease detection, awareness, and treatment in primary care</article-title>. <source>JAMA</source> <volume>286</volume>: <fpage>1317</fpage>–<lpage>1324</lpage>.</citation>
</ref>
<ref id="bibr70-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hirsch</surname><given-names>A.T.</given-names></name>
<name><surname>Hartman</surname><given-names>L.</given-names></name>
<name><surname>Town</surname><given-names>R.J.</given-names></name>
<name><surname>Virnig</surname><given-names>B.A.</given-names></name>
</person-group> (<year>2008</year>) <article-title>National health care costs of peripheral arterial disease in the Medicare population</article-title>. <source>Vasc Med</source> <volume>13</volume>: <fpage>209</fpage>–<lpage>215</lpage>.</citation>
</ref>
<ref id="bibr71-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hirsch</surname><given-names>A.T.</given-names></name>
<name><surname>Haskal</surname><given-names>Z.J.</given-names></name>
<name><surname>Hertzer</surname><given-names>N.R.</given-names></name>
<name><surname>Bakal</surname><given-names>C.W.</given-names></name>
<name><surname>Creager</surname><given-names>M.A.</given-names></name>
<name><surname>Halperin</surname><given-names>J.L.</given-names></name>
<etal/>
</person-group>. (<year>2006</year>) <article-title>ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients with Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; Transatlantic Inter-Society Consensus; and Vascular Disease Foundation</article-title>. <source>Circulation</source> <volume>113</volume>: <fpage>e463</fpage>–<lpage>e654</lpage>.</citation>
</ref>
<ref id="bibr72-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hirsch</surname><given-names>A.T.</given-names></name>
<name><surname>Treat-Jacobson</surname><given-names>D.</given-names></name>
<name><surname>Lando</surname><given-names>H.A.</given-names></name>
<name><surname>Hatsukami</surname><given-names>D.K.</given-names></name>
</person-group> (<year>1997</year>) <article-title>The role of tobacco cessation, antiplatelet and lipid-lowering therapies in the treatment of peripheral arterial disease</article-title>. <source>Vasc Med</source> <volume>2</volume>: <fpage>243</fpage>–<lpage>251</lpage>.</citation>
</ref>
<ref id="bibr73-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hirsh</surname><given-names>J.</given-names></name>
<name><surname>Dalen</surname><given-names>J.E.</given-names></name>
<name><surname>Fuster</surname><given-names>V.</given-names></name>
<name><surname>Harker</surname><given-names>L.B.</given-names></name>
<name><surname>Patrono</surname><given-names>C.</given-names></name>
<name><surname>Roth</surname><given-names>G.</given-names></name>
</person-group> (<year>1995</year>) <article-title>Aspirin and other platelet-active drugs. the relationship among dose, effectiveness, and side effects</article-title>. <source>Chest</source> <volume>108</volume>: <fpage>247S</fpage>–<lpage>257S</lpage>.</citation>
</ref>
<ref id="bibr74-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ho</surname><given-names>W.K.</given-names></name>
<name><surname>Hankey</surname><given-names>G.J.</given-names></name>
<name><surname>Eikelboom</surname><given-names>J.W.</given-names></name>
</person-group> (<year>2004</year>) <article-title>Prevention of coronary heart disease with aspirin and clopidogrel: efficacy, safety, costs and cost-effectiveness</article-title>. <source>Expert Opin Pharmacother</source> <volume>5</volume>: <fpage>493</fpage>–<lpage>503</lpage>.</citation>
</ref>
<ref id="bibr75-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hobbs</surname><given-names>S.D.</given-names></name>
<name><surname>Bradbury</surname><given-names>A.W.</given-names></name>
</person-group> (<year>2003</year>) <article-title>Smoking cessation strategies in patients with peripheral arterial disease: an evidence-based approach</article-title>. <source>Eur J Vasc Endovasc Surg</source> <volume>26</volume>: <fpage>341</fpage>–<lpage>347</lpage>.</citation>
</ref>
<ref id="bibr76-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Howell</surname><given-names>M.A.</given-names></name>
<name><surname>Colgan</surname><given-names>M.P.</given-names></name>
<name><surname>Seeger</surname><given-names>R.W.</given-names></name>
<name><surname>Ramsey</surname><given-names>D.E.</given-names></name>
<name><surname>Sumner</surname><given-names>D.S.</given-names></name>
</person-group> (<year>1989</year>) <article-title>Relationship of severity of lower limb peripheral vascular disease to mortality and morbidity: a six-year follow-up study</article-title>. <source>J Vasc Surg</source> <volume>9</volume>: <fpage>691</fpage>–<lpage>696</lpage>; <comment>discussion 696–697</comment>.</citation>
</ref>
<ref id="bibr77-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hsia</surname><given-names>J.</given-names></name>
<name><surname>Simon</surname><given-names>J.A.</given-names></name>
<name><surname>Lin</surname><given-names>F.</given-names></name>
<name><surname>Applegate</surname><given-names>W.B.</given-names></name>
<name><surname>Vogt</surname><given-names>M.T.</given-names></name>
<name><surname>Hunninghake</surname><given-names>D.</given-names></name>
<etal/>
</person-group>. (<year>2000</year>) <article-title>Peripheral arterial disease in randomized trial of estrogen with progestin in women with coronary heart disease: the Heart and Estrogen/Progestin Replacement Study</article-title>. <source>Circulation</source> <volume>102</volume>: <fpage>2228</fpage>–<lpage>2232</lpage>.</citation>
</ref>
<ref id="bibr78-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hughes</surname><given-names>S.</given-names></name>
</person-group> (<year>2008</year>) <article-title>Niacin plus laropiprant ‘not approvable’ in US</article-title>. <source>HeartWire</source> <day>29</day> <month>April</month>.</citation>
</ref>
<ref id="bibr79-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hurt</surname><given-names>R.</given-names></name>
<name><surname>Sachs</surname><given-names>D.</given-names></name>
<name><surname>Glover</surname><given-names>E.</given-names></name>
<name><surname>Offord</surname><given-names>K.</given-names></name>
<name><surname>Johnston</surname><given-names>J.</given-names></name>
<name><surname>Dale</surname><given-names>L.</given-names></name>
<etal/>
</person-group>. (<year>1997</year>) <article-title>A comparison of sustained-release bupropion and placebo for smoking cessation</article-title>. <source>N Engl J Med</source> <volume>337</volume>: <fpage>1195</fpage>–<lpage>1202</lpage>.</citation>
</ref>
<ref id="bibr80-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ingolfsson</surname><given-names>I.O.</given-names></name>
<name><surname>Sigurdsson</surname><given-names>G.</given-names></name>
<name><surname>Sigvaldason</surname><given-names>H.</given-names></name>
<name><surname>Thorgeirsson</surname><given-names>G.</given-names></name>
<name><surname>Sigfusson</surname><given-names>N.</given-names></name>
</person-group> (<year>1994</year>) <article-title>A marked decline in the prevalence and incidence of intermittent claudication in Icelandic men 1968–1986: a strong relationship to smoking and serum cholesterol – the Reykjavik Study</article-title>. <source>J Clin Epidemiol</source> <volume>47</volume>: <fpage>1237</fpage>–<lpage>1243</lpage>.</citation>
</ref>
<ref id="bibr81-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Insull</surname><given-names>W.</given-names><suffix>Jr</suffix></name>
</person-group> (<year>2006</year>) <article-title>Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review</article-title>. <source>South Med J</source> <volume>99</volume>: <fpage>257</fpage>–<lpage>273</lpage>.</citation>
</ref>
<ref id="bibr82-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ishii</surname><given-names>H.</given-names></name>
<name><surname>Kumada</surname><given-names>Y.</given-names></name>
<name><surname>Toriyama</surname><given-names>T.</given-names></name>
<name><surname>Aoyama</surname><given-names>T.</given-names></name>
<name><surname>Takahashi</surname><given-names>H.</given-names></name>
<name><surname>Yamada</surname><given-names>S.</given-names></name>
<etal/>
</person-group>. (<year>2008</year>) <article-title>Cilostazol improves long-term patency after percutaneous transluminal angioplasty in hemodialysis patients with peripheral artery disease</article-title>. <source>Clin J Am Soc Nephrol</source> <volume>3</volume>: <fpage>1034</fpage>–<lpage>1040</lpage>.</citation>
</ref>
<ref id="bibr83-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jill</surname><given-names>J.F.B.</given-names></name>
<name><surname>John</surname><given-names>D.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Results of the randomized, placebo-controlled Clopidogrel and Acetylsalicylic Acid in Bypass Surgery for Peripheral Arterial Disease (CASPAR) trial</article-title>. <source>J Vasc Surg</source> <volume>52</volume>: <fpage>825</fpage>–<lpage>833.e822</lpage>.</citation>
</ref>
<ref id="bibr84-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jin</surname><given-names>F.Y.</given-names></name>
<name><surname>Kamanna</surname><given-names>V.S.</given-names></name>
<name><surname>Kashyap</surname><given-names>M.L.</given-names></name>
</person-group> (<year>1997</year>) <article-title>Niacin decreases removal of high-density lipoprotein apolipoprotein A-I but not cholesterol ester by Hep G2 cells. Implication for reverse cholesterol transport</article-title>. <source>Arterioscler Thromb Vasc Biol</source> <volume>17</volume>: <fpage>2020</fpage>–<lpage>2028</lpage>.</citation>
</ref>
<ref id="bibr85-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Johannesson</surname><given-names>A.</given-names></name>
<name><surname>Larsson</surname><given-names>G.U.</given-names></name>
<name><surname>Ramstrand</surname><given-names>N.</given-names></name>
<name><surname>Turkiewicz</surname><given-names>A.</given-names></name>
<name><surname>Wirehn</surname><given-names>A.B.</given-names></name>
<name><surname>Atroshi</surname><given-names>I.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Incidence of lower-limb amputation in the diabetic and nondiabetic general population: a 10-year population-based cohort study of initial unilateral and contralateral amputations and reamputations</article-title>. <source>Diabetes Care</source> <volume>32</volume>: <fpage>275</fpage>–<lpage>280</lpage>.</citation>
</ref>
<ref id="bibr86-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>John</surname><given-names>J.P.K.</given-names></name>
<name><surname>Philip</surname><given-names>T.S.</given-names></name>
<name><surname>Eric De</surname><given-names>G.</given-names></name>
<name><surname>Enrico</surname><given-names>V.</given-names></name>
</person-group> (<year>2005</year>) <article-title>Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia: design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial</article-title>. <source>Am Heart J</source> <volume>149</volume>: <fpage>234</fpage>–<lpage>239</lpage>.</citation>
</ref>
<ref id="bibr87-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jonason</surname><given-names>T.</given-names></name>
<name><surname>Ringqvist</surname><given-names>I.</given-names></name>
</person-group> (<year>1985</year>) <article-title>Factors of prognostic importance for subsequent rest pain in patients with intermittent claudication</article-title>. <source>Acta Med Scand</source> <volume>218</volume>: <fpage>27</fpage>–<lpage>33</lpage>.</citation>
</ref>
<ref id="bibr88-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jorenby</surname><given-names>D.</given-names></name>
<name><surname>Hays</surname><given-names>J.</given-names></name>
<name><surname>Rigotti</surname><given-names>N.</given-names></name>
<name><surname>Azoulay</surname><given-names>S.</given-names></name>
<name><surname>Watsky</surname><given-names>E.</given-names></name>
<name><surname>Williams</surname><given-names>K.</given-names></name>
<etal/>
</person-group>. (<year>2006</year>) <article-title>Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial</article-title>. <source>JAMA</source> <volume>296</volume>: <fpage>56</fpage>–<lpage>63</lpage>.</citation>
</ref>
<ref id="bibr89-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jun</surname><given-names>M.</given-names></name>
<name><surname>Foote</surname><given-names>C.</given-names></name>
<name><surname>Lv</surname><given-names>J.</given-names></name>
<name><surname>Neal</surname><given-names>B.</given-names></name>
<name><surname>Patel</surname><given-names>A.</given-names></name>
<name><surname>Nicholls</surname><given-names>S.J.</given-names></name>
<etal/>
</person-group>. (<year>2010</year>) <article-title>Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis</article-title>. <source>The Lancet</source> <volume>375</volume>: <fpage>1875</fpage>–<lpage>1884</lpage>.</citation>
</ref>
<ref id="bibr90-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kannel</surname><given-names>W.B.</given-names></name>
<name><surname>Skinner</surname><given-names>J.J.</given-names><suffix>Jr</suffix></name>
<name><surname>Schwartz</surname><given-names>M.J.</given-names></name>
<name><surname>Shurtleff</surname><given-names>D.</given-names></name>
</person-group> (<year>1970</year>) <article-title>Intermittent claudication. Incidence in the Framingham Study</article-title>. <source>Circulation</source> <volume>41</volume>: <fpage>875</fpage>–<lpage>883</lpage>.</citation>
</ref>
<ref id="bibr91-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kastrati</surname><given-names>A.</given-names></name>
<name><surname>Schömig</surname><given-names>A.</given-names></name>
<name><surname>Elezi</surname><given-names>S.</given-names></name>
<name><surname>Schühlen</surname><given-names>H.</given-names></name>
<name><surname>Dirschinger</surname><given-names>J.</given-names></name>
<name><surname>Hadamitzky</surname><given-names>M.</given-names></name>
<etal/>
</person-group>. (<year>1997</year>) <article-title>Predictive factors of restenosis after coronary stent placement</article-title>. <source>J Am Coll Cardiol</source> <volume>30</volume>: <fpage>1428</fpage>–<lpage>1436</lpage>.</citation>
</ref>
<ref id="bibr92-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Khan</surname><given-names>S.</given-names></name>
<name><surname>Cleanthis</surname><given-names>M.</given-names></name>
<name><surname>Smout</surname><given-names>J.</given-names></name>
<name><surname>Flather</surname><given-names>M.</given-names></name>
<name><surname>Stansby</surname><given-names>G.</given-names></name>
</person-group> (<year>2005</year>) <article-title>Life-style modification in peripheral arterial disease</article-title>. <source>Eur J Vasc Endovasc Surg</source> <volume>29</volume>: <fpage>2</fpage>–<lpage>9</lpage>.</citation>
</ref>
<ref id="bibr93-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Klein</surname><given-names>S.</given-names></name>
<name><surname>Sheard</surname><given-names>N.F.</given-names></name>
<name><surname>Pi-Sunyer</surname><given-names>X.</given-names></name>
<name><surname>Daly</surname><given-names>A.</given-names></name>
<name><surname>Wylie-Rosett</surname><given-names>J.</given-names></name>
<name><surname>Kulkarni</surname><given-names>K.</given-names></name>
<etal/>
</person-group>. (<year>2004</year>) <article-title>Weight management through lifestyle modification for the prevention and management of type 2 diabetes: rationale and strategies: A statement of the American Diabetes Association, the North American Association for the Study of Obesity, and the American Society for Clinical Nutrition</article-title>. <source>Diabetes Care</source> <volume>27</volume>: <fpage>2067</fpage>–<lpage>2073</lpage>.</citation>
</ref>
<ref id="bibr94-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kudchodkar</surname><given-names>B.J.</given-names></name>
<name><surname>Wilson</surname><given-names>J.</given-names></name>
<name><surname>Lacko</surname><given-names>A.</given-names></name>
<name><surname>Dory</surname><given-names>L.</given-names></name>
</person-group> (<year>2000</year>) <article-title>Hyperbaric oxygen reduces the progression and accelerates the regression of atherosclerosis in rabbits</article-title>. <source>Arterioscler Thromb Vasc Biol</source> <volume>20</volume>: <fpage>1637</fpage>–<lpage>1643</lpage>.</citation>
</ref>
<ref id="bibr95-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kullo</surname><given-names>I.J.</given-names></name>
<name><surname>Bailey</surname><given-names>K.R.</given-names></name>
<name><surname>Kardia</surname><given-names>S.L.</given-names></name>
<name><surname>Mosley</surname><given-names>T.H.</given-names><suffix>Jr</suffix></name>
<name><surname>Boerwinkle</surname><given-names>E.</given-names></name>
<name><surname>Turner</surname><given-names>S.T.</given-names></name>
</person-group> (<year>2003</year>) <article-title>Ethnic differences in peripheral arterial disease in the NHLBI Genetic Epidemiology Network of Arteriopathy (GENOA) study</article-title>. <source>Vasc Med</source> <volume>8</volume>: <fpage>237</fpage>–<lpage>242</lpage>.</citation>
</ref>
<ref id="bibr96-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kyriakides</surname><given-names>Z.S.</given-names></name>
<name><surname>Petinakis</surname><given-names>P.</given-names></name>
<name><surname>Kaklamanis</surname><given-names>L.</given-names></name>
<name><surname>Sbarouni</surname><given-names>E.</given-names></name>
<name><surname>Karayannakos</surname><given-names>P.</given-names></name>
<name><surname>Iliopoulos</surname><given-names>D.</given-names></name>
<etal/>
</person-group>. (<year>2001</year>) <article-title>Intramuscular administration of estrogen may promote angiogenesis and perfusion in a rabbit model of chronic limb ischemia</article-title>. <source>Cardiovasc Res</source> <volume>49</volume>: <fpage>626</fpage>–<lpage>633</lpage>.</citation>
</ref>
<ref id="bibr97-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lamy</surname><given-names>A.</given-names></name>
<name><surname>Yusuf</surname><given-names>S.</given-names></name>
<name><surname>Pogue</surname><given-names>J.</given-names></name>
<name><surname>Gafni</surname><given-names>A.</given-names></name>
</person-group> (<year>2003</year>) <article-title>Cost implications of the use of ramipril in high-risk patients based on the Heart Outcomes Prevention Evaluation (HOPE) study</article-title>. <source>Circulation</source> <volume>107</volume>: <fpage>960</fpage>–<lpage>965</lpage>.</citation>
</ref>
<ref id="bibr98-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lederman</surname><given-names>R.J.</given-names></name>
<name><surname>Mendelsohn</surname><given-names>F.O.</given-names></name>
<name><surname>Anderson</surname><given-names>R.D.</given-names></name>
<name><surname>Saucedo</surname><given-names>J.F.</given-names></name>
<name><surname>Tenaglia</surname><given-names>A.N.</given-names></name>
<name><surname>Hermiller</surname><given-names>J.B.</given-names></name>
<etal/>
</person-group>. (<year>2002</year>) <article-title>Therapeutic Angiogenesis with Recombinant Fibroblast Growth Factor-2 for Intermittent Claudication (the TRAFFIC study): a randomised trial</article-title>. <source>Lancet</source> <volume>359</volume>: <fpage>2053</fpage>–<lpage>2058</lpage>.</citation>
</ref>
<ref id="bibr99-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Leon</surname><given-names>M.B.</given-names></name>
<name><surname>Baim</surname><given-names>D.S.</given-names></name>
<name><surname>Popma</surname><given-names>J.J.</given-names></name>
<name><surname>Gordon</surname><given-names>P.C.</given-names></name>
<name><surname>Cutlip</surname><given-names>D.E.</given-names></name>
<name><surname>Ho</surname><given-names>K.K.</given-names></name>
<etal/>
</person-group>. (<year>1998</year>) <article-title>A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators</article-title>. <source>N Engl J Med</source> <volume>339</volume>: <fpage>1665</fpage>–<lpage>1671</lpage>.</citation>
</ref>
<ref id="bibr100-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lewis</surname><given-names>E.J.</given-names></name>
<name><surname>Hunsicker</surname><given-names>L.G.</given-names></name>
<name><surname>Clarke</surname><given-names>W.R.</given-names></name>
<name><surname>Berl</surname><given-names>T.</given-names></name>
<name><surname>Pohl</surname><given-names>M.A.</given-names></name>
<name><surname>Lewis</surname><given-names>J.B.</given-names></name>
<etal/>
</person-group>. (<year>2001</year>) <article-title>Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes</article-title>. <source>N Engl J Med</source> <volume>345</volume>: <fpage>851</fpage>–<lpage>860</lpage>.</citation>
</ref>
<ref id="bibr101-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Libby</surname><given-names>P.</given-names></name>
<name><surname>Simon</surname><given-names>D.I.</given-names></name>
</person-group> (<year>2001</year>) <article-title>Inflammation and thrombosis: the clot thickens</article-title>. <source>Circulation</source> <volume>103</volume>: <fpage>1718</fpage>–<lpage>1720</lpage>.</citation>
</ref>
<ref id="bibr102-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lonn</surname><given-names>E.</given-names></name>
<name><surname>Yusuf</surname><given-names>S.</given-names></name>
<name><surname>Arnold</surname><given-names>M.J.</given-names></name>
<name><surname>Sheridan</surname><given-names>P.</given-names></name>
<name><surname>Pogue</surname><given-names>J.</given-names></name>
<name><surname>Micks</surname><given-names>M.</given-names></name>
<etal/>
</person-group>. (<year>2006</year>) <article-title>Homocysteine lowering with folic acid and b vitamins in vascular disease</article-title>. <source>N Engl J Med</source> <volume>354</volume>: <fpage>1567</fpage>–<lpage>1577</lpage>.</citation>
</ref>
<ref id="bibr103-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lowensteyn</surname><given-names>I.</given-names></name>
<name><surname>Coupal</surname><given-names>L.</given-names></name>
<name><surname>Zowall</surname><given-names>H.</given-names></name>
<name><surname>Grover</surname><given-names>S.A.</given-names></name>
</person-group> (<year>2000</year>) <article-title>The cost-effectiveness of exercise training for the primary and secondary prevention of cardiovascular disease</article-title>. <source>J Cardiopulm Rehabil</source> <volume>20</volume>: <fpage>147</fpage>–<lpage>155</lpage>.</citation>
</ref>
<ref id="bibr104-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Manabe</surname><given-names>H.</given-names></name>
<name><surname>Okonkwo</surname><given-names>D.O.</given-names></name>
<name><surname>Gainer</surname><given-names>J.L.</given-names></name>
<name><surname>Clarke</surname><given-names>R.H.</given-names></name>
<name><surname>Lee</surname><given-names>K.S.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Protection against focal ischemic injury to the brain by trans-sodium crocetinate. Laboratory investigation</article-title>. <source>J Neurosurg</source> <volume>113</volume>: <fpage>802</fpage>–<lpage>809</lpage>.</citation>
</ref>
<ref id="bibr105-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Matsui</surname><given-names>K.</given-names></name>
<name><surname>Ikeda</surname><given-names>U.</given-names></name>
<name><surname>Murakami</surname><given-names>Y.</given-names></name>
<name><surname>Yoshioka</surname><given-names>T.</given-names></name>
<name><surname>Shimada</surname><given-names>K.</given-names></name>
</person-group> (<year>2003</year>) <article-title>Intravenous prostaglandin e1 reduces monocyte chemoattractant protein-1 levels in peripheral arterial obstructive disease</article-title>. <source>Am Heart J</source> <volume>145</volume>: <fpage>330</fpage>–<lpage>333</lpage>.</citation>
</ref>
<ref id="bibr106-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Matsuo</surname><given-names>H.</given-names></name>
<name><surname>Shigematsu</surname><given-names>H.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Patient-based outcomes using the walking impairment questionnaire for patients with peripheral arterial occlusive disease treated with Lipo-PGE1</article-title>. <source>Circ J</source> <volume>74</volume>: <fpage>365</fpage>–<lpage>370</lpage>.</citation>
</ref>
<ref id="bibr107-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>McDermott</surname><given-names>M.M.</given-names></name>
<name><surname>Feinglass</surname><given-names>J.</given-names></name>
<name><surname>Slavensky</surname><given-names>R.</given-names></name>
<name><surname>Pearce</surname><given-names>W.H.</given-names></name>
</person-group> (<year>1994</year>) <article-title>The Ankle-Brachial Index as a predictor of survival in patients with peripheral vascular disease</article-title>. <source>J Gen Intern Med</source> <volume>9</volume>: <fpage>445</fpage>–<lpage>449</lpage>.</citation>
</ref>
<ref id="bibr108-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>McKenna</surname><given-names>M.</given-names></name>
<name><surname>Wolfson</surname><given-names>S.</given-names></name>
<name><surname>Kuller</surname><given-names>L.</given-names></name>
</person-group> (<year>1991</year>) <article-title>The ratio of ankle and arm arterial pressure as an independent predictor of mortality</article-title>. <source>Atherosclerosis</source> <volume>87</volume>: <fpage>119</fpage>–<lpage>128</lpage>.</citation>
</ref>
<ref id="bibr109-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Meijer</surname><given-names>W.T.</given-names></name>
<name><surname>Grobbee</surname><given-names>D.E.</given-names></name>
<name><surname>Hunink</surname><given-names>M.G.</given-names></name>
<name><surname>Hofman</surname><given-names>A.</given-names></name>
<name><surname>Hoes</surname><given-names>A.W.</given-names></name>
</person-group> (<year>2000</year>) <article-title>Determinants of peripheral arterial disease in the elderly: the Rotterdam study</article-title>. <source>Arch Intern Med</source> <volume>160</volume>: <fpage>2934</fpage>–<lpage>2938</lpage>.</citation>
</ref>
<ref id="bibr110-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Merchant</surname><given-names>A.T.</given-names></name>
<name><surname>Hu</surname><given-names>F.B.</given-names></name>
<name><surname>Spiegelman</surname><given-names>D.</given-names></name>
<name><surname>Willett</surname><given-names>W.C.</given-names></name>
<name><surname>Rimm</surname><given-names>E.B.</given-names></name>
<name><surname>Ascherio</surname><given-names>A.</given-names></name>
</person-group> (<year>2003</year>) <article-title>Dietary fiber reduces peripheral arterial disease risk in men</article-title>. <source>J Nutr</source> <volume>133</volume>: <fpage>3658</fpage>–<lpage>3663</lpage>.</citation>
</ref>
<ref id="bibr111-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Milio</surname><given-names>G.</given-names></name>
<name><surname>Coppola</surname><given-names>G.</given-names></name>
<name><surname>Novo</surname><given-names>S.</given-names></name>
</person-group> (<year>2006</year>) <article-title>The effects of prostaglandin e-1 in patients with intermittent claudication</article-title>. <source>Cardiovasc Hematol Disord Drug Targets</source> <volume>6</volume>: <fpage>71</fpage>–<lpage>76</lpage>.</citation>
</ref>
<ref id="bibr112-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mitka</surname><given-names>M.</given-names></name>
</person-group> (<year>2008</year>) <article-title>Cholesterol drug controversy continues</article-title>. <source>JAMA</source> <volume>299</volume>: <year>2266</year>.</citation>
</ref>
<ref id="bibr113-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mohler</surname><given-names>E.</given-names></name>
<name><surname>Gainer</surname><given-names>J.</given-names></name>
<name><surname>Whitten</surname><given-names>K.</given-names></name>
<name><surname>Eraso</surname><given-names>L.</given-names></name>
<name><surname>Thanaporn</surname><given-names>P.</given-names></name>
<name><surname>Bauer</surname><given-names>T.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Evaluation of trans sodium crocetinate on safety and exercise performance in patients with peripheral artery disease and intermittent claudication</article-title>. <source>Vasc Med</source> <volume>16</volume>: <fpage>346</fpage>–<lpage>353</lpage>.</citation>
</ref>
<ref id="bibr114-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mohler</surname><given-names>E.R.</given-names><suffix>3rd</suffix></name>
<name><surname>Hiatt</surname><given-names>W.R.</given-names></name>
<name><surname>Creager</surname><given-names>M.A.</given-names></name>
</person-group> (<year>2003</year>) <article-title>Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease</article-title>. <source>Circulation</source> <volume>108</volume>: <fpage>1481</fpage>–<lpage>1486</lpage>.</citation>
</ref>
<ref id="bibr115-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mohsen</surname><given-names>S.</given-names></name>
<name><surname>Wassim</surname><given-names>F.</given-names></name>
<name><surname>Isam</surname><given-names>A.-K.</given-names></name>
<name><surname>Koch</surname><given-names>J.M.</given-names></name>
<name><surname>Joseph</surname><given-names>S.</given-names></name>
<name><surname>Dale</surname><given-names>A.</given-names></name>
</person-group> (<year>2004</year>) <article-title>Usefulness of hyperbaric oxygen therapy to inhibit restenosis after percutaneous coronary intervention for acute myocardial infarction or unstable angina pectoris</article-title>. <source>Am J Cardiol</source> <volume>93</volume>: <fpage>1533</fpage>–<lpage>1535</lpage></citation>
</ref>
<ref id="bibr116-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Muntner</surname><given-names>P.</given-names></name>
<name><surname>Wildman</surname><given-names>R.P.</given-names></name>
<name><surname>Reynolds</surname><given-names>K.</given-names></name>
<name><surname>Desalvo</surname><given-names>K.B.</given-names></name>
<name><surname>Chen</surname><given-names>J.</given-names></name>
<name><surname>Fonseca</surname><given-names>V.</given-names></name>
</person-group> (<year>2005</year>) <article-title>Relationship between HbA1c level and peripheral arterial disease</article-title>. <source>Diabetes Care</source> <volume>28</volume>: <fpage>1981</fpage>–<lpage>1987</lpage>.</citation>
</ref>
<ref id="bibr117-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Murabito</surname><given-names>J.M.</given-names></name>
<name><surname>D’Agostino</surname><given-names>R.B.</given-names></name>
<name><surname>Silbershatz</surname><given-names>H.</given-names></name>
<name><surname>Wilson</surname><given-names>P.W.F.</given-names></name>
</person-group> (<year>1997</year>) <article-title>Intermittent claudication: a risk profile from the Framingham Heart Study</article-title>. <source>Circulation</source> <volume>96</volume>: <fpage>44</fpage>–<lpage>49</lpage>.</citation>
</ref>
<ref id="bibr118-1753944712437359">
<citation citation-type="confproc">
<person-group person-group-type="author">
<name><surname>Nakajima</surname><given-names>T.</given-names></name>
<name><surname>Lehdonvirta</surname><given-names>V.</given-names></name>
<name><surname>Tokunaga</surname><given-names>E.</given-names></name>
<name><surname>Kimura</surname><given-names>H.</given-names></name>
</person-group> (<year>2008</year>) <article-title>Reflecting human behavior to motivate desirable lifestyle</article-title>, <conf-name>Proceedings of the 7th ACM Conference on Designing Interactive Systems</conf-name>. <publisher-name>ACM</publisher-name>: <publisher-loc>Cape Town, South Africa</publisher-loc>.</citation>
</ref>
<ref id="bibr119-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Neal</surname><given-names>B.</given-names></name>
<name><surname>Macmahon</surname><given-names>S.</given-names></name>
<name><surname>Chapman</surname><given-names>N.</given-names></name>
</person-group> (<year>2000</year>) <article-title>Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists’ Collaboration</article-title>. <source>Lancet</source> <volume>356</volume>: <fpage>1955</fpage>–<lpage>1964</lpage>.</citation>
</ref>
<ref id="bibr120-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Neri Serneri</surname><given-names>G.G.</given-names></name>
<name><surname>Coccheri</surname><given-names>S.</given-names></name>
<name><surname>Marubini</surname><given-names>E.</given-names></name>
<name><surname>Violi</surname><given-names>F.</given-names></name>
</person-group> (<year>2004</year>) <article-title>Picotamide, a combined inhibitor of thromboxane a2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study</article-title>. <source>Eur Heart J</source> <volume>25</volume>: <fpage>1845</fpage>–<lpage>1852</lpage>.</citation>
</ref>
<ref id="bibr121-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ness</surname><given-names>J.</given-names></name>
<name><surname>Aronow</surname><given-names>W.S.</given-names></name>
</person-group> (<year>1999</year>) <article-title>Prevalence of coexistence of coronary artery disease, ischemic stroke, and peripheral arterial disease in older persons, mean age 80 years, in an academic hospital-based geriatrics practice</article-title>. <source>J Am Geriatr Soc</source> <volume>47</volume>: <fpage>1255</fpage>–<lpage>1256</lpage>.</citation>
</ref>
<ref id="bibr122-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Newman</surname><given-names>A.B.</given-names></name>
<name><surname>Sutton-Tyrrell</surname><given-names>K.</given-names></name>
<name><surname>Vogt</surname><given-names>M.T.</given-names></name>
<name><surname>Kuller</surname><given-names>L.H.</given-names></name>
</person-group> (<year>1993</year>) <article-title>Morbidity and mortality in hypertensive adults with a low ankle/arm blood pressure index</article-title>. <source>JAMA</source> <volume>270</volume>: <fpage>487</fpage>–<lpage>489</lpage>.</citation>
</ref>
<ref id="bibr123-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nissen</surname><given-names>S.E.</given-names></name>
<name><surname>Nicholls</surname><given-names>S.J.</given-names></name>
<name><surname>Sipahi</surname><given-names>I.</given-names></name>
<name><surname>Libby</surname><given-names>P.</given-names></name>
<name><surname>Raichlen</surname><given-names>J.S.</given-names></name>
<name><surname>Ballantyne</surname><given-names>C.M.</given-names></name>
<etal/>
</person-group>. (<year>2006</year>) <article-title>Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the Asteroid trial</article-title>. <source>JAMA</source> <volume>295</volume>: <fpage>1556</fpage>–<lpage>1565</lpage>.</citation>
</ref>
<ref id="bibr124-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Norgren</surname><given-names>L.</given-names></name>
<name><surname>Hiatt</surname><given-names>W.R.</given-names></name>
<name><surname>Dormandy</surname><given-names>J.A.</given-names></name>
<name><surname>Hirsch</surname><given-names>A.T.</given-names></name>
<name><surname>Jaff</surname><given-names>M.R.</given-names></name>
<name><surname>Diehm</surname><given-names>C.</given-names></name>
<etal/>
</person-group>. (<year>2010</year>) <article-title>The next 10 years in the management of peripheral artery disease: perspectives from the ‘PAD 2009’ Conference</article-title>. <source>Eur J Vasc Endovasc Surg</source> <volume>40</volume>: <fpage>375</fpage>–<lpage>380</lpage>.</citation>
</ref>
<ref id="bibr125-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Norgren</surname><given-names>L.</given-names></name>
<name><surname>Hiatt</surname><given-names>W.R.</given-names></name>
<name><surname>Dormandy</surname><given-names>J.A.</given-names></name>
<name><surname>Nehler</surname><given-names>M.R.</given-names></name>
<name><surname>Harris</surname><given-names>K.A.</given-names></name>
<name><surname>Fowkes</surname><given-names>F.G.</given-names></name>
<etal/>
</person-group>. (<year>2007</year>) <article-title>Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II)</article-title>. <source>Eur J Vasc Endovasc Surg</source> <volume>33</volume>(<supplement>Suppl. 1</supplement>): <fpage>S1</fpage>–<lpage>S75</lpage>.</citation>
</ref>
<ref id="bibr126-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Osamu</surname><given-names>I.</given-names></name>
<name><surname>Shinsuke</surname><given-names>N.</given-names></name>
<name><surname>Masaaki</surname><given-names>U.</given-names></name>
<name><surname>Takakazu</surname><given-names>M.</given-names></name>
<name><surname>Masafumi</surname><given-names>K.</given-names></name>
<name><surname>Seiki</surname><given-names>N.</given-names></name>
</person-group> (<year>2008</year>) <article-title>Cilostazol reduces restenosis after endovascular therapy in patients with femoropopliteal lesions</article-title>. <source>J Vasc Surg</source> <volume>48</volume>: <fpage>144</fpage>–<lpage>149</lpage>.</citation>
</ref>
<ref id="bibr127-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Oscar</surname><given-names>H.G.</given-names></name>
<name><surname>Deidra</surname><given-names>H.M.</given-names></name>
<name><surname>Stacy</surname><given-names>S.K.</given-names></name>
<name><surname>David</surname><given-names>C.C.</given-names></name>
<name><surname>Scott</surname><given-names>L.S.</given-names></name>
<name><surname>Michael</surname><given-names>B.F.</given-names></name>
<etal/>
</person-group>. (<year>2009</year>) <article-title>Regulation of vascular smooth muscle cell expression and function of matrix metalloproteinases is mediated by estrogen and progesterone exposure</article-title>. <source>J Vasc Surg</source> <volume>49</volume>: <fpage>185</fpage>–<lpage>191</lpage>.</citation>
</ref>
<ref id="bibr128-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ostergren</surname><given-names>J.</given-names></name>
<name><surname>Sleight</surname><given-names>P.</given-names></name>
<name><surname>Dagenais</surname><given-names>G.</given-names></name>
<name><surname>Danisa</surname><given-names>K.</given-names></name>
<name><surname>Bosch</surname><given-names>J.</given-names></name>
<name><surname>Qilong</surname><given-names>Y.</given-names></name>
<etal/>
</person-group>. (<year>2004</year>) <article-title>Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease</article-title>. <source>Eur Heart J</source> <volume>25</volume>: <fpage>17</fpage>–<lpage>24</lpage>.</citation>
</ref>
<ref id="bibr129-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ott</surname><given-names>S.M.</given-names></name>
<name><surname>Lacroix</surname><given-names>A.Z.</given-names></name>
<name><surname>Ichikawa</surname><given-names>L.E.</given-names></name>
<name><surname>Scholes</surname><given-names>D.</given-names></name>
<name><surname>Barlow</surname><given-names>W.E.</given-names></name>
</person-group> (<year>2003</year>) <article-title>Effect of low-dose thiazide diuretics on plasma lipids: results from a double-blind, randomized clinical trial in older men and women</article-title>. <source>J Am Geriatr Soc</source> <volume>51</volume>: <fpage>340</fpage>–<lpage>347</lpage>.</citation>
</ref>
<ref id="bibr130-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Packer</surname><given-names>M.</given-names></name>
<name><surname>Carver</surname><given-names>J.R.</given-names></name>
<name><surname>Rodeheffer</surname><given-names>R.J.</given-names></name>
<name><surname>Ivanhoe</surname><given-names>R.J.</given-names></name>
<name><surname>Dibianco</surname><given-names>R.</given-names></name>
<name><surname>Zeldis</surname><given-names>S.M.</given-names></name>
<etal/>
</person-group>. (<year>1991</year>) <article-title>Effect of oral milrinone on mortality in severe chronic heart failure</article-title>. <source>N Engl J Med</source> <volume>325</volume>: <fpage>1468</fpage>–<lpage>1475</lpage>.</citation>
</ref>
<ref id="bibr131-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Paolini</surname><given-names>J.F.</given-names></name>
<name><surname>Bays</surname><given-names>H.E.</given-names></name>
<name><surname>Ballantyne</surname><given-names>C.M.</given-names></name>
<name><surname>Davidson</surname><given-names>M.</given-names></name>
<name><surname>Pasternak</surname><given-names>R.</given-names></name>
<name><surname>Maccubbin</surname><given-names>D.</given-names></name>
<etal/>
</person-group>. (<year>2008</year>) <article-title>Extended-release niacin/laropiprant: reducing niacin-induced flushing to better realize the benefit of niacin in improving cardiovascular risk factors</article-title>. <source>Cardiol Clin</source> <volume>26</volume>: <fpage>547</fpage>–<lpage>560</lpage>.</citation>
</ref>
<ref id="bibr132-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Plouin</surname><given-names>P.F.</given-names></name>
<name><surname>Clement</surname><given-names>D.L.</given-names></name>
<name><surname>Boccalon</surname><given-names>H.</given-names></name>
<name><surname>Dormandy</surname><given-names>J.</given-names></name>
<name><surname>Durand-Zaleski</surname><given-names>I.</given-names></name>
<name><surname>Fowkes</surname><given-names>G.</given-names></name>
<etal/>
</person-group>. (<year>2003</year>) <article-title>A clinical approach to the management of a patient with suspected renovascular disease who presents with leg ischemia</article-title>. <source>Int Angiol</source> <volume>22</volume>: <fpage>333</fpage>–<lpage>339</lpage>.</citation>
</ref>
<ref id="bibr133-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Poldermans</surname><given-names>D.</given-names></name>
<name><surname>Boersma</surname><given-names>E.</given-names></name>
<name><surname>Bax</surname><given-names>J.J.</given-names></name>
<name><surname>Thomson</surname><given-names>I.R.</given-names></name>
<name><surname>Paelinck</surname><given-names>B.</given-names></name>
<name><surname>Van</surname><given-names>De</given-names></name>
<name><surname>Ven</surname><given-names>L.L.</given-names></name>
<etal/>
</person-group>. (<year>2001</year>) <article-title>Bisoprolol reduces cardiac death and myocardial infarction in high-risk patients as long as 2 years after successful major vascular surgery</article-title>. <source>Eur Heart J</source> <volume>22</volume>: <fpage>1353</fpage>–<lpage>1358</lpage>.</citation>
</ref>
<ref id="bibr134-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Poldermans</surname><given-names>D.</given-names></name>
<name><surname>Boersma</surname><given-names>E.</given-names></name>
<name><surname>Bax</surname><given-names>J.J.</given-names></name>
<name><surname>Thomson</surname><given-names>I.R.</given-names></name>
<name><surname>Van</surname><given-names>De</given-names></name>
<name><surname>Ven</surname><given-names>L.L.</given-names></name>
<name><surname>Blankensteijn</surname><given-names>J.D.</given-names></name>
<etal/>
</person-group>. (<year>1999</year>) <article-title>The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group</article-title>. <source>N Engl J Med</source> <volume>341</volume>: <fpage>1789</fpage>–<lpage>1794</lpage>.</citation>
</ref>
<ref id="bibr135-1753944712437359">
<citation citation-type="journal">
<collab>PROGRESS Collaborative Group</collab> (<year>2001</year>) <article-title>Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack</article-title>. <source>Lancet</source> <volume>358</volume>: <fpage>1033</fpage>-<lpage>1041</lpage>.</citation>
</ref>
<ref id="bibr136-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Radack</surname><given-names>K.</given-names></name>
<name><surname>Deck</surname><given-names>C.</given-names></name>
</person-group> (<year>1991</year>) <article-title>Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials</article-title>. <source>Arch Intern Med</source> <volume>151</volume>: <fpage>1769</fpage>–<lpage>1776</lpage>.</citation>
</ref>
<ref id="bibr137-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ray</surname><given-names>B.</given-names></name>
<name><surname>Chetter</surname><given-names>I.C.</given-names></name>
<name><surname>Lee</surname><given-names>H.L.</given-names></name>
<name><surname>Ettelaie</surname><given-names>C.</given-names></name>
<name><surname>McCollum</surname><given-names>P.T.</given-names></name>
</person-group> (<year>2007</year>) <article-title>Plasma tissue factor is a predictor for restenosis after femoropopliteal angioplasty</article-title>. <source>Br J Surg</source> <volume>94</volume>: <fpage>1092</fpage>–<lpage>1095</lpage>.</citation>
</ref>
<ref id="bibr138-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Regensteiner</surname><given-names>J.G.</given-names></name>
<name><surname>Ware</surname><given-names>J.E.</given-names></name>
<name><surname>McCarthy</surname><given-names>W.J.</given-names></name>
<name><surname>Zhang</surname><given-names>P.</given-names></name>
<name><surname>Forbes</surname><given-names>W.P.</given-names></name>
<name><surname>Heckman</surname><given-names>J.</given-names></name>
<etal/>
</person-group>. (<year>2002</year>) <article-title>Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: meta-analysis of six randomized controlled trials</article-title>. <source>J Am Geriatr Soc</source> <volume>50</volume>: <fpage>1939</fpage>–<lpage>1946</lpage>.</citation>
</ref>
<ref id="bibr139-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ridker</surname><given-names>P.M.</given-names></name>
<name><surname>Cushman</surname><given-names>M.</given-names></name>
<name><surname>Stampfer</surname><given-names>M.J.</given-names></name>
<name><surname>Tracy</surname><given-names>R.P.</given-names></name>
<name><surname>Hennekens</surname><given-names>C.H.</given-names></name>
</person-group> (<year>1998</year>) <article-title>Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease</article-title>. <source>Circulation</source> <volume>97</volume>: <fpage>425</fpage>–<lpage>428</lpage>.</citation>
</ref>
<ref id="bibr140-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ridker</surname><given-names>P.M.</given-names></name>
<name><surname>Stampfer</surname><given-names>M.J.</given-names></name>
<name><surname>Rifai</surname><given-names>N.</given-names></name>
</person-group> (<year>2001</year>) <article-title>Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease</article-title>. <source>JAMA</source> <volume>285</volume>: <fpage>2481</fpage>–<lpage>2485</lpage>.</citation>
</ref>
<ref id="bibr141-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rippel</surname><given-names>D.</given-names></name>
<name><surname>Ignaszewski</surname><given-names>A.</given-names></name>
<name><surname>Frohlich</surname><given-names>J.</given-names></name>
</person-group> (<year>2007</year>) <article-title>Lack of benefit in treating high homocysteine levels with vitamins</article-title>. <source>BCMJ</source> <volume>49</volume>: <fpage>20</fpage>–<lpage>23</lpage>.</citation>
</ref>
<ref id="bibr142-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rollins</surname><given-names>B.J.</given-names></name>
</person-group> (<year>1997</year>) <article-title>Chemokines</article-title>. <source>Blood</source> <volume>90</volume>: <fpage>909</fpage>–<lpage>928</lpage>.</citation>
</ref>
<ref id="bibr143-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rosenberg</surname><given-names>L.</given-names></name>
<name><surname>Palmer</surname><given-names>J.R.</given-names></name>
<name><surname>Shapiro</surname><given-names>S.</given-names></name>
</person-group> (<year>1990</year>) <article-title>Decline in the risk of myocardial infarction among women who stop smoking</article-title>. <source>N Engl J Med</source> <volume>322</volume>: <fpage>213</fpage>–<lpage>217</lpage>.</citation>
</ref>
<ref id="bibr144-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rosenfeldt</surname><given-names>F.L.</given-names></name>
<name><surname>Haas</surname><given-names>S.J.</given-names></name>
<name><surname>Krum</surname><given-names>H.</given-names></name>
<name><surname>Hadj</surname><given-names>A.</given-names></name>
<name><surname>Ng</surname><given-names>K.</given-names></name>
<name><surname>Leong</surname><given-names>J.Y.</given-names></name>
<etal/>
</person-group>. (<year>2007</year>) <article-title>Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials</article-title>. <source>J Hum Hypertens</source> <volume>21</volume>: <fpage>297</fpage>–<lpage>306</lpage>.</citation>
</ref>
<ref id="bibr145-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rouis</surname><given-names>M.</given-names></name>
<name><surname>Adamy</surname><given-names>C.</given-names></name>
<name><surname>Duverger</surname><given-names>N.</given-names></name>
<name><surname>Lesnik</surname><given-names>P.</given-names></name>
<name><surname>Horellou</surname><given-names>P.</given-names></name>
<name><surname>Moreau</surname><given-names>M.</given-names></name>
<etal/>
</person-group>. (<year>1999</year>) <article-title>Adenovirus-mediated overexpression of tissue inhibitor of metalloproteinase-1 reduces atherosclerotic lesions in apolipoprotein e–deficient mice</article-title>. <source>Circulation</source> <volume>100</volume>: <fpage>533</fpage>–<lpage>540</lpage>.</citation>
</ref>
<ref id="bibr146-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ruifrok</surname><given-names>W.P.</given-names></name>
<name><surname>De Boer</surname><given-names>R.A.</given-names></name>
<name><surname>Iwakura</surname><given-names>A.</given-names></name>
<name><surname>Silver</surname><given-names>M.</given-names></name>
<name><surname>Kusano</surname><given-names>K.</given-names></name>
<name><surname>Tio</surname><given-names>R.A.</given-names></name>
<etal/>
</person-group>. (<year>2009</year>) <article-title>Estradiol-induced, endothelial progenitor cell-mediated neovascularization in male mice with hind-limb ischemia</article-title>. <source>Vasc Med</source> <volume>14</volume>: <fpage>29</fpage>–<lpage>36</lpage>.</citation>
</ref>
<ref id="bibr147-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sacks</surname><given-names>F.M.</given-names></name>
<name><surname>Svetkey</surname><given-names>L.P.</given-names></name>
<name><surname>Vollmer</surname><given-names>W.M.</given-names></name>
<name><surname>Appel</surname><given-names>L.J.</given-names></name>
<name><surname>Bray</surname><given-names>G.A.</given-names></name>
<name><surname>Harsha</surname><given-names>D.</given-names></name>
<etal/>
</person-group>. (<year>2001</year>) <article-title>Effects on blood pressure of reduced dietary sodium and the dietary approaches to stop hypertension (DASH) diet</article-title>. <source>N Engl J Med</source> <volume>344</volume>: <fpage>3</fpage>–<lpage>10</lpage>.</citation>
</ref>
<ref id="bibr148-1753944712437359">
<citation citation-type="web">
<collab>SAGE Group</collab> (<year>2010</year>) <article-title>The SAGE Group releases new estimates for the united states prevalence of peripheral artery disease (PAD) and critical limb ischemia (CLI)</article-title>. <publisher-loc>Atlanta</publisher-loc>. <comment>Available at: <ext-link ext-link-type="uri" xlink:href="http://thesagegroup.us/pages/news/press-releases.php">http://thesagegroup.us/pages/news/press-releases.php</ext-link></comment> (<access-date>accessed 22 January 2012</access-date>).</citation>
</ref>
<ref id="bibr149-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Samuel</surname><given-names>A.</given-names></name>
<name><surname>Kristian</surname><given-names>B.F.</given-names></name>
<name><surname>Lawrence</surname><given-names>J.</given-names></name>
<name><surname>Ernesto</surname><given-names>L.S.</given-names></name>
<name><surname>Stephane</surname><given-names>R.</given-names></name>
<name><surname>Paul</surname><given-names>P.</given-names></name>
<etal/>
</person-group>. (<year>2009</year>) <article-title>Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review</article-title>. <source>Am J Med</source> <volume>122</volume>: <fpage>962.e961</fpage>–<lpage>962.e968</lpage>.</citation>
</ref>
<ref id="bibr150-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sanganalmath</surname><given-names>S.K.</given-names></name>
<name><surname>Babick</surname><given-names>A.P.</given-names></name>
<name><surname>Barta</surname><given-names>J.</given-names></name>
<name><surname>Kumamoto</surname><given-names>H.</given-names></name>
<name><surname>Takeda</surname><given-names>N.</given-names></name>
<name><surname>Dhalla</surname><given-names>N.S.</given-names></name>
</person-group> (<year>2008</year>) <article-title>Antiplatelet therapy attenuates subcellular remodelling in congestive heart failure</article-title>. <source>J Cell Mol Med</source> <volume>12</volume>: <fpage>1728</fpage>–<lpage>1738</lpage>.</citation>
</ref>
<ref id="bibr151-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schillinger</surname><given-names>M.</given-names></name>
<name><surname>Exner</surname><given-names>M.</given-names></name>
<name><surname>Mlekusch</surname><given-names>W.</given-names></name>
<name><surname>Haumer</surname><given-names>M.</given-names></name>
<name><surname>Rumpold</surname><given-names>H.</given-names></name>
<name><surname>Ahmadi</surname><given-names>R.</given-names></name>
<etal/>
</person-group>. (<year>2003</year>) <article-title>Endovascular revascularization below the knee: 6-month results and predictive value of C-reactive protein level</article-title>. <source>Radiology</source> <volume>227</volume>: <fpage>419</fpage>–<lpage>425</lpage>.</citation>
</ref>
<ref id="bibr152-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schillinger</surname><given-names>M.</given-names></name>
<name><surname>Exner</surname><given-names>M.</given-names></name>
<name><surname>Mlekusch</surname><given-names>W.</given-names></name>
<name><surname>Haumer</surname><given-names>M.</given-names></name>
<name><surname>Sabeti</surname><given-names>S.</given-names></name>
<name><surname>Ahmadi</surname><given-names>R.</given-names></name>
<etal/>
</person-group>. (<year>2004</year>) <article-title>Effect of smoking on restenosis during the 1st year after lower-limb endovascular interventions 1</article-title>. <source>Radiology</source> <volume>231</volume>: <fpage>831</fpage>–<lpage>838</lpage>.</citation>
</ref>
<ref id="bibr153-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Selvin</surname><given-names>E.</given-names></name>
<name><surname>Erlinger</surname><given-names>T.P.</given-names></name>
</person-group> (<year>2004</year>) <article-title>Prevalence of and risk factors for peripheral arterial disease in the united states: Results from the National Health and Nutrition Examination Survey, 1999–2000</article-title>. <source>Circulation</source> <volume>110</volume>: <fpage>738</fpage>–<lpage>743</lpage>.</citation>
</ref>
<ref id="bibr154-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shaikh</surname><given-names>S.</given-names></name>
<name><surname>Nicholson</surname><given-names>L.F.</given-names></name>
</person-group> (<year>2008</year>) <article-title>Advanced glycation end products induce in vitro cross-linking of alpha-synuclein and accelerate the process of intracellular inclusion body formation</article-title>. <source>J Neurosci Res</source> <volume>86</volume>: <fpage>2071</fpage>–<lpage>2082</lpage>.</citation>
</ref>
<ref id="bibr155-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shyu</surname><given-names>K.G.</given-names></name>
<name><surname>Chang</surname><given-names>H.</given-names></name>
<name><surname>Wang</surname><given-names>B.W.</given-names></name>
<name><surname>Kuan</surname><given-names>P.</given-names></name>
</person-group> (<year>2003</year>) <article-title>Intramuscular vascular endothelial growth factor gene therapy in patients with chronic critical leg ischemia</article-title>. <source>Am J Med</source> <volume>114</volume>: <fpage>85</fpage>–<lpage>92</lpage>.</citation>
</ref>
<ref id="bibr156-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sigvant</surname><given-names>B.</given-names></name>
<name><surname>Henriksson</surname><given-names>M.</given-names></name>
<name><surname>Lundin</surname><given-names>F.</given-names></name>
<name><surname>Wahlberg</surname><given-names>E.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Asymptomatic peripheral arterial disease: is pharmacological prevention of cardiovascular risk cost-effective?</article-title> <source>Eur J Cardiovasc Prev Rehabil</source> <volume>18</volume>: <fpage>254</fpage>–<lpage>261</lpage>.</citation>
</ref>
<ref id="bibr157-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Silagy</surname><given-names>C.</given-names></name>
<name><surname>Mant</surname><given-names>D.</given-names></name>
<name><surname>Fowler</surname><given-names>G.</given-names></name>
<name><surname>Lodge</surname><given-names>M.</given-names></name>
</person-group> (<year>1994</year>) <article-title>Meta-analysis on efficacy of nicotine replacement therapies in smoking cessation</article-title>. <source>The Lancet</source> <volume>343</volume>: <fpage>139</fpage>–<lpage>142</lpage>.</citation>
</ref>
<ref id="bibr158-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Simm</surname><given-names>A.</given-names></name>
<name><surname>Wagner</surname><given-names>J.</given-names></name>
<name><surname>Gursinsky</surname><given-names>T.</given-names></name>
<name><surname>Nass</surname><given-names>N.</given-names></name>
<name><surname>Friedrich</surname><given-names>I.</given-names></name>
<name><surname>Schinzel</surname><given-names>R.</given-names></name>
<etal/>
</person-group>. (<year>2007</year>) <article-title>Advanced glycation endproducts: a biomarker for age as an outcome predictor after cardiac surgery?</article-title> <source>Exp Gerontol</source> <volume>42</volume>: <fpage>668</fpage>–<lpage>675</lpage>.</citation>
</ref>
<ref id="bibr159-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Singh</surname><given-names>S.</given-names></name>
<name><surname>Loke</surname><given-names>Y.K.</given-names></name>
<name><surname>Spangler</surname><given-names>J.G.</given-names></name>
<name><surname>Furberg</surname><given-names>C.D.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis</article-title>. <source>CMAJ</source> <volume>183</volume>: <fpage>1359</fpage>–<lpage>1366</lpage>.</citation>
</ref>
<ref id="bibr160-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Soga</surname><given-names>Y.</given-names></name>
<name><surname>Yokoi</surname><given-names>H.</given-names></name>
<name><surname>Kawasaki</surname><given-names>T.</given-names></name>
<name><surname>Nakashima</surname><given-names>H.</given-names></name>
<name><surname>Tsurugida</surname><given-names>M.</given-names></name>
<name><surname>Hikichi</surname><given-names>Y.</given-names></name>
<etal/>
</person-group>. (<year>2009</year>) <article-title>Efficacy of cilostazol after endovascular therapy for femoropopliteal artery disease in patients with intermittent claudication</article-title>. <source>J Am Coll Cardiol</source> <volume>53</volume>: <fpage>48</fpage>–<lpage>53</lpage>.</citation>
</ref>
<ref id="bibr161-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Speidl</surname><given-names>W.S.</given-names></name>
<name><surname>Exner</surname><given-names>M.</given-names></name>
<name><surname>Amighi</surname><given-names>J.</given-names></name>
<name><surname>Mlekusch</surname><given-names>W.</given-names></name>
<name><surname>Sabeti</surname><given-names>S.</given-names></name>
<name><surname>Kastl</surname><given-names>S.P.</given-names></name>
<etal/>
</person-group>. (<year>2007</year>) <article-title>Complement component C5a predicts restenosis after superficial femoral artery balloon angioplasty</article-title>. <source>Journal of Endovascular Therapy</source> <volume>14</volume>: <fpage>62</fpage>–<lpage>69</lpage>.</citation>
</ref>
<ref id="bibr162-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sprigg</surname><given-names>N.</given-names></name>
<name><surname>Gray</surname><given-names>L.</given-names></name>
<name><surname>England</surname><given-names>T.</given-names></name>
<name><surname>Willmot</surname><given-names>M.</given-names></name>
<name><surname>Zhao</surname><given-names>L.</given-names></name>
<name><surname>Sare</surname><given-names>G.</given-names></name>
<etal/>
</person-group>. (<year>2008</year>) <article-title>A randomised controlled trial of triple antiplatelet therapy (aspirin, clopidogrel and dipyridamole) in the secondary prevention of stroke: Safety, tolerability and feasibility (ISRCTN 83673558)</article-title>. <source>PLoS One</source> <volume>3</volume>: <fpage>e2852</fpage>.</citation>
</ref>
<ref id="bibr163-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stead</surname><given-names>L.F.</given-names></name>
<name><surname>Perera</surname><given-names>R.</given-names></name>
<name><surname>Lancaster</surname><given-names>T.</given-names></name>
</person-group> (<year>2006</year>) <article-title>Telephone counselling for smoking cessation</article-title>. <source>Cochrane Database Syst Rev</source> <volume>3</volume>: <comment>CD002850</comment>.</citation>
</ref>
<ref id="bibr164-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stephens</surname><given-names>J.</given-names></name>
<name><surname>Hagler</surname><given-names>D.</given-names></name>
<name><surname>Clark</surname><given-names>E.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Got PAD? Hidden dangers revealed with ABI</article-title>. <source>J Vasc Nurs</source> <volume>29</volume>: <fpage>153</fpage>–<lpage>157</lpage>.</citation>
</ref>
<ref id="bibr165-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stirban</surname><given-names>A.</given-names></name>
<name><surname>Negrean</surname><given-names>M.</given-names></name>
<name><surname>Stratmann</surname><given-names>B.</given-names></name>
<name><surname>Gawlowski</surname><given-names>T.</given-names></name>
<name><surname>Horstmann</surname><given-names>T.</given-names></name>
<name><surname>Gotting</surname><given-names>C.</given-names></name>
<etal/>
</person-group>. (<year>2006</year>) <article-title>Benfotiamine prevents macro- and microvascular endothelial dysfunction and oxidative stress following a meal rich in advanced glycation end products in individuals with type 2 diabetes</article-title>. <source>Diabetes Care</source> <volume>29</volume>: <fpage>2064</fpage>–<lpage>2071</lpage>.</citation>
</ref>
<ref id="bibr166-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stoffers</surname><given-names>H.</given-names></name>
<name><surname>Rinkens</surname><given-names>P.</given-names></name>
<name><surname>Kester</surname><given-names>A.D.</given-names></name>
<name><surname>Kaiser</surname><given-names>V.</given-names></name>
<name><surname>Knottnerus</surname><given-names>J.A.</given-names></name>
</person-group> (<year>1996</year>) <article-title>The prevalence of asymptomatic and unrecognized peripheral arterial occlusive disease</article-title>. <source>Int J Epidemiol</source> <volume>25</volume>: <fpage>282</fpage>–<lpage>290</lpage>.</citation>
</ref>
<ref id="bibr167-1753944712437359">
<citation citation-type="journal">
<collab>Stroke Prevention in Atrial Fibrillation II Study</collab> (<year>1994</year>) <article-title>Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: stroke Prevention in Atrial Fibrillation II Study</article-title>. <source>Lancet</source> <volume>343</volume>: <fpage>687</fpage>–<lpage>691</lpage>.</citation>
</ref>
<ref id="bibr168-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Taylor</surname><given-names>L.M.</given-names><suffix>Jr</suffix></name>
<name><surname>Defrang</surname><given-names>R.D.</given-names></name>
<name><surname>Harris</surname><given-names>E.J.</given-names><suffix>Jr</suffix></name>
<name><surname>Porter</surname><given-names>J.M.</given-names></name>
</person-group> (<year>1991</year>) <article-title>The association of elevated plasma homocyst(e)ine with progression of symptomatic peripheral arterial disease</article-title>. <source>J Vasc Surg</source> <volume>13</volume>: <fpage>128</fpage>–<lpage>136</lpage>.</citation>
</ref>
<ref id="bibr169-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Terje</surname><given-names>R.P.</given-names></name>
<name><surname>John</surname><given-names>K.</given-names></name>
<name><surname>Kalevi</surname><given-names>P.</given-names></name>
<name><surname>Anders</surname><given-names>G.O.</given-names></name>
<name><surname>Thomas</surname><given-names>J.C.</given-names></name>
<name><surname>Thomas</surname><given-names>A.M.</given-names></name>
<etal/>
</person-group>. (<year>1998</year>) <article-title>Effect of simvastatin on ischemic signs and symptoms in the Scandinavian Simvastatin Survival Study (4s)</article-title>. <source>Am J Cardiol</source> <volume>81</volume>: <fpage>333</fpage>–<lpage>335</lpage>.</citation>
</ref>
<ref id="bibr170-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Thompson</surname><given-names>P.D.</given-names></name>
<name><surname>Zimet</surname><given-names>R.</given-names></name>
<name><surname>Forbes</surname><given-names>W.P.</given-names></name>
<name><surname>Zhang</surname><given-names>P.</given-names></name>
</person-group> (<year>2002</year>) <article-title>Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication</article-title>. <source>Am J Cardiol</source> <volume>90</volume>: <fpage>1314</fpage>–<lpage>1319</lpage>.</citation>
</ref>
<ref id="bibr171-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Timaran</surname><given-names>C.H.</given-names></name>
<name><surname>Stevens</surname><given-names>S.L.</given-names></name>
<name><surname>Grandas</surname><given-names>O.H.</given-names></name>
<name><surname>Piercy</surname><given-names>K.T.</given-names></name>
<name><surname>Freeman</surname><given-names>M.B.</given-names></name>
<name><surname>Goldman</surname><given-names>M.H.</given-names></name>
</person-group> (<year>2000</year>) <article-title>Influence of hormone replacement therapy on graft patency after femoropopliteal bypass grafting</article-title>. <source>J Vasc Surg</source> <volume>32</volume>: <fpage>506</fpage>–<lpage>516</lpage>; <fpage>516</fpage>–<lpage>518</lpage>.</citation>
</ref>
<ref id="bibr172-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tonstad</surname><given-names>S.</given-names></name>
<name><surname>Farsang</surname><given-names>C.</given-names></name>
<name><surname>Klaene</surname><given-names>G.</given-names></name>
<name><surname>Lewis</surname><given-names>K.</given-names></name>
<name><surname>Manolis</surname><given-names>A.</given-names></name>
<name><surname>Perruchoud</surname><given-names>A.P.</given-names></name>
<etal/>
</person-group>. (<year>2003</year>) <article-title>Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study</article-title>. <source>Eur Heart J</source> <volume>24</volume>: <fpage>946</fpage>–<lpage>955</lpage>.</citation>
</ref>
<ref id="bibr173-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tretjakovs</surname><given-names>P</given-names></name>
<name><surname>Jurka</surname><given-names>A.</given-names></name>
<name><surname>Stifts</surname><given-names>A.</given-names></name>
<name><surname>Ivanova</surname><given-names>P.</given-names></name>
<name><surname>Krievins</surname><given-names>D.</given-names></name>
<name><surname>Jansone</surname><given-names>A.</given-names></name>
<etal/>
</person-group>. (<year>2006</year>) <article-title>The effect of serotonin 5-HT2 receptor inhibitor on vasomotor responses</article-title>. <source>Vasc Dis Prev</source> <volume>3</volume>: <fpage>297</fpage>–<lpage>304</lpage>.</citation>
</ref>
<ref id="bibr174-1753944712437359">
<citation citation-type="journal">
<collab>UK Prospective Diabetes Study (UKPDS) Group</collab> (<year>1998</year>) <article-title>Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)</article-title>. <source>Lancet</source> <volume>352</volume>: <fpage>837</fpage>–<lpage>853</lpage>.</citation>
</ref>
<ref id="bibr175-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Urbonaviciene</surname><given-names>G.</given-names></name>
<name><surname>Frystyk</surname><given-names>J.</given-names></name>
<name><surname>Flyvbjerg</surname><given-names>A.</given-names></name>
<name><surname>Urbonavicius</surname><given-names>S.</given-names></name>
<name><surname>Henneberg</surname><given-names>E.W.</given-names></name>
<name><surname>Lindholt</surname><given-names>J.S.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Markers of inflammation in relation to long-term cardiovascular mortality in patients with lower-extremity peripheral arterial disease</article-title>. <source>Int J Cardiol</source> <day>2</day> <month>April</month> [<comment>Epub ahead of print</comment>]</citation>
</ref>
<ref id="bibr176-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Van Hattum</surname><given-names>E.S.</given-names></name>
<name><surname>Algra</surname><given-names>A.</given-names></name>
<name><surname>Lawson</surname><given-names>J.A.</given-names></name>
<name><surname>Eikelboom</surname><given-names>B.C.</given-names></name>
<name><surname>Moll</surname><given-names>F.L.</given-names></name>
<name><surname>Tangelder</surname><given-names>M.J.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Bleeding increases the risk of ischemic events in patients with peripheral arterial disease</article-title>. <source>Circulation</source> <volume>120</volume>: <fpage>1569</fpage>–<lpage>1576</lpage>.</citation>
</ref>
<ref id="bibr177-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Villines</surname><given-names>T.C.</given-names></name>
<name><surname>Stanek</surname><given-names>E.J.</given-names></name>
<name><surname>Devine</surname><given-names>P.J.</given-names></name>
<name><surname>Turco</surname><given-names>M.</given-names></name>
<name><surname>Miller</surname><given-names>M.</given-names></name>
<name><surname>Weissman</surname><given-names>N.J.</given-names></name>
<etal/>
</person-group>. (<year>2010</year>) <article-title>The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration</article-title>. <source>J Am Coll Cardiol</source> <volume>55</volume>: <fpage>2721</fpage>–<lpage>2726</lpage>.</citation>
</ref>
<ref id="bibr178-1753944712437359">
<citation citation-type="journal">
<collab>VITATOPS Trial Study Group</collab> (<year>2010</year>) <article-title>B Vitamins in patients with recent transient ischaemic attack or stroke in the Vitamins to Prevent Stroke (VITATOPS) trial: a randomised, double-blind, parallel, placebo-controlled trial</article-title>. <source>The Lancet Neurology</source> <volume>9</volume>: <fpage>855</fpage>–<lpage>865</lpage>.</citation>
</ref>
<ref id="bibr179-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vogt</surname><given-names>M.T.</given-names></name>
<name><surname>Cauley</surname><given-names>J.A.</given-names></name>
<name><surname>Kuller</surname><given-names>L.H.</given-names></name>
<name><surname>Hulley</surname><given-names>S.B.</given-names></name>
</person-group> (<year>1993</year>) <article-title>Prevalence and correlates of lower extremity arterial disease in elderly women</article-title>. <source>Am J Epidemiol</source> <volume>137</volume>: <fpage>559</fpage>–<lpage>568</lpage>.</citation>
</ref>
<ref id="bibr180-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Weitz</surname><given-names>J.I.</given-names></name>
<name><surname>Byrne</surname><given-names>J.</given-names></name>
<name><surname>Clagett</surname><given-names>G.P.</given-names></name>
<name><surname>Farkouh</surname><given-names>M.E.</given-names></name>
<name><surname>Porter</surname><given-names>J.M.</given-names></name>
<name><surname>Sackett</surname><given-names>D.L.</given-names></name>
<etal/>
</person-group>. (<year>1996</year>) <article-title>Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review</article-title>. <source>Circulation</source> <volume>94</volume>: <fpage>3026</fpage>–<lpage>3049</lpage>.</citation>
</ref>
<ref id="bibr181-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>White</surname><given-names>A.R.</given-names></name>
<name><surname>Rampes</surname><given-names>H.</given-names></name>
<name><surname>Liu</surname><given-names>J.P.</given-names></name>
<name><surname>Stead</surname><given-names>L.F.</given-names></name>
<name><surname>Campbell</surname><given-names>J.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Acupuncture and related interventions for smoking cessation</article-title>. <source>Cochrane Database Syst Rev</source>: <comment>CD000009</comment>.</citation>
</ref>
<ref id="bibr182-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wild</surname><given-names>S.H.</given-names></name>
<name><surname>Byrne</surname><given-names>C.D.</given-names></name>
<name><surname>Smith</surname><given-names>F.B.</given-names></name>
<name><surname>Lee</surname><given-names>A.J.</given-names></name>
<name><surname>Fowkes</surname><given-names>F.G.</given-names></name>
</person-group> (<year>2006</year>) <article-title>Low ankle-brachial pressure index predicts increased risk of cardiovascular disease independent of the metabolic syndrome and conventional cardiovascular risk factors in the Edinburgh Artery Study</article-title>. <source>Diabetes Care</source> <volume>29</volume>: <fpage>637</fpage>–<lpage>642</lpage>.</citation>
</ref>
<ref id="bibr183-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Willigendael</surname><given-names>E.M.</given-names></name>
<name><surname>Teijink</surname><given-names>J.A.</given-names></name>
<name><surname>Bartelink</surname><given-names>M.L.</given-names></name>
<name><surname>Kuiken</surname><given-names>B.W.</given-names></name>
<name><surname>Boiten</surname><given-names>J.</given-names></name>
<name><surname>Moll</surname><given-names>F.L.</given-names></name>
<etal/>
</person-group>. (<year>2004</year>) <article-title>Influence of smoking on incidence and prevalence of peripheral arterial disease</article-title>. <source>J Vasc Surg</source> <volume>40</volume>: <fpage>1158</fpage>–<lpage>1165</lpage>.</citation>
</ref>
<ref id="bibr184-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Winkel</surname><given-names>T.A.</given-names></name>
<name><surname>Hoeks</surname><given-names>S.E.</given-names></name>
<name><surname>Schouten</surname><given-names>O.</given-names></name>
<name><surname>Zeymer</surname><given-names>U.</given-names></name>
<name><surname>Limbourg</surname><given-names>T.</given-names></name>
<name><surname>Baumgartner</surname><given-names>I.</given-names></name>
<etal/>
</person-group>. (<year>2010</year>) <article-title>Prognosis of atrial fibrillation in patients with symptomatic peripheral arterial disease: data from the Reduction of Atherothrombosis for Continued Health (REACH) Registry</article-title>. <source>Eur J Vasc Endovasc Surg</source> <volume>40</volume>: <fpage>9</fpage>–<lpage>16</lpage>.</citation>
</ref>
<ref id="bibr185-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wiviott</surname><given-names>S.D.</given-names></name>
<name><surname>Braunwald</surname><given-names>E.</given-names></name>
<name><surname>McCabe</surname><given-names>C.H.</given-names></name>
<name><surname>Montalescot</surname><given-names>G.</given-names></name>
<name><surname>Ruzyllo</surname><given-names>W.</given-names></name>
<name><surname>Gottlieb</surname><given-names>S.</given-names></name>
<etal/>
</person-group>. (<year>2007a</year>) <article-title>Prasugrel versus clopidogrel in patients with acute coronary syndromes</article-title>. <source>N Engl J Med</source> <volume>357</volume>: <fpage>2001</fpage>–<lpage>2015</lpage>.</citation>
</ref>
<ref id="bibr186-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wiviott</surname><given-names>S.D.</given-names></name>
<name><surname>Trenk</surname><given-names>D.</given-names></name>
<name><surname>Frelinger</surname><given-names>A.L.</given-names></name>
<name><surname>O’Donoghue</surname><given-names>M.</given-names></name>
<name><surname>Neumann</surname><given-names>F.J.</given-names></name>
<name><surname>Michelson</surname><given-names>A.D.</given-names></name>
<etal/>
</person-group>. (<year>2007b</year>) <article-title>Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 Trial</article-title>. <source>Circulation</source> <volume>116</volume>: <fpage>2923</fpage>–<lpage>2932</lpage>.</citation>
</ref>
<ref id="bibr187-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wu</surname><given-names>P.</given-names></name>
<name><surname>Wilson</surname><given-names>K.</given-names></name>
<name><surname>Dimoulas</surname><given-names>P.</given-names></name>
<name><surname>Mills</surname><given-names>E.</given-names></name>
</person-group> (<year>2006</year>) <article-title>Effectiveness of smoking cessation therapies: a systematic review and meta-analysis</article-title>. <source>BMC Public Health</source> <volume>6</volume>: <fpage>300</fpage>.</citation>
</ref>
<ref id="bibr188-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yusuf</surname><given-names>S.</given-names></name>
<name><surname>Sleight</surname><given-names>P.</given-names></name>
<name><surname>Pogue</surname><given-names>J.</given-names></name>
<name><surname>Bosch</surname><given-names>J.</given-names></name>
<name><surname>Davies</surname><given-names>R.</given-names></name>
<name><surname>Dagenais</surname><given-names>G.</given-names></name>
</person-group> (<year>2000</year>) <article-title>Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators</article-title>. <source>N Engl J Med</source> <volume>342</volume>: <fpage>145</fpage>–<lpage>153</lpage>.</citation>
</ref>
<ref id="bibr189-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yusuf</surname><given-names>S.</given-names></name>
<name><surname>Zhao</surname><given-names>F.</given-names></name>
<name><surname>Mehta</surname><given-names>S.R.</given-names></name>
<name><surname>Chrolavicius</surname><given-names>S.</given-names></name>
<name><surname>Tognoni</surname><given-names>G.</given-names></name>
<name><surname>Fox</surname><given-names>K.K.</given-names></name>
<etal/>
</person-group>. (<year>2001</year>) <article-title>Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation</article-title>. <source>N Engl J Med</source> <volume>345</volume>: <fpage>1506</fpage>–<lpage>1506</lpage>.</citation>
</ref>
<ref id="bibr190-1753944712437359">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zimmerman</surname><given-names>G.A.</given-names></name>
<name><surname>Meistrell</surname><given-names>M.</given-names><suffix>3rd</suffix></name>
<name><surname>Bloom</surname><given-names>O.</given-names></name>
<name><surname>Cockroft</surname><given-names>K.M.</given-names></name>
<name><surname>Bianchi</surname><given-names>M.</given-names></name>
<name><surname>Risucci</surname><given-names>D.</given-names></name>
<etal/>
</person-group>. (<year>1995</year>) <article-title>Neurotoxicity of advanced glycation endproducts during focal stroke and neuroprotective effects of aminoguanidine</article-title>. <source>Proc Natl Acad Sci U S A</source> <volume>92</volume>: <fpage>3744</fpage>–<lpage>3748</lpage>.</citation>
</ref></ref-list>
</back>
</article>